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Abstract 
Human immunodeficiency virus (HIV) and its gradual weakening of the immune system is an 
ever growing threat. Acquired immune deficiency syndrome (AIDS), the final stage of HIV, 
renders a person vulnerable to various opportunistic infections, which in the end lead to death. 
Apart from intensive vaccine studies, treatment research mainly focuses on preventing the 
individual HIV enzymes (reverse transcriptase, integrase and protease) from performing their 
functions. Entry inhibitors, however, block viral entry into the cell, while antisense drugs lock 
onto the viral genome to keep it from functioning. 
 
In this study production of active recombinant HIV-1 protease and integrase was attempted for 
future drug screening programs. HIV-1 protease was cloned into a pET28b(+) vector and 
expressed in ROSETTA(DE3)pLysS cells. The protein was purified using a nickel-affinity 
column utilizing the hexa-histidine tag encoded by the vector. Gel filtration chromatography was 
attempted after refolding of the protease, but protease yield seemed to decrease with the 
additional purification step. Partially purified protease was characterized with kinetic studies. 
Kinetic parameters of HIV-1 protease were determined to be Km = 592 µM, Vmax = 0.59 µM/min 
and kcat = 31 s-1. 
 
HIV-1 integrase, which was cloned into a pET15b vector, was expressed in E. coli BL21(DE3) 
cells. The coding sequence had been mutated to introduce the amino acid substitutions F185K 
and C280S, increasing solubility of the protein. The first step in purification of this protein was 
nickel-affinity chromatography, after which cation exchange chromatography was attempted. 
HIV-1 integrase concentration was low throughout experiments and no clear elution from the 
cation exchange column could be observed. A non-radioactive enzyme linked HIV-1 integrase 
assay failed to detect integrase activity. Modifications to future studies of the integrase are 
suggested in the chapter involved. 
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Chapter 1 
 
Literature Review 
1.1 
      
Human Immunodeficiency Virus (HIV) and Acquired    
 
Immune Deficiency Syndrome (AIDS) 
1.1.1 
 
HIV and related viruses 
The human immunodeficiency virus (HIV) is a one of the most complex viruses that infect 
humans and is the causative agent of acquired immunodeficiency syndrome (AIDS). The genetic 
variety of the virus among people and even inside one person makes this virus particularly hard 
to target with drugs or vaccines. In addition, accumulation of new and diverse information 
concerning many aspects of the HIV, such as functioning and interaction with its host, course of 
the disease, origins and transmission of HIV, immunity and tolerance to HIV makes fighting this 
virus even more challenging. Among the infectious diseases, AIDS is now the leading cause of 
death worldwide. Therefore, the task of finding an effective vaccine or drug for HIV is of great 
importance (Velikovic et al., 2008). 
 
There are several viruses that infect primates and cause similar effects as HIV (pathogenesis and 
immune system responses). These viruses are called Simian Immunodeficiency Viruses (SIV). 
Primate models are often used in testing vaccines and drugs for HIV. The fact that there is no 
completely suitable primate model for studying HIV, either in terms of the number of animals 
available or in terms of how rapidly the results are obtained decreases the rate of the scientific 
progress in this direction (Joag, 2000). 
 
HIV belongs to a class of viruses called retroviruses, which have genes composed of ribonucleic 
acid (RNA) molecules. Once inside the cell the virus uses an enzyme called reverse transcriptase 
to convert its RNA into DNA, which is incorporated into the host cell’s genome. HIV also 
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belongs to a subgroup of retroviruses known as lentiviruses, or “slow” viruses. The course of 
infection of lentiviruses is characterized by a long interval between initial infection and the onset 
of serious symptoms (Shuljak, 2006). 
 
The first cases of acquired immune deficiency syndrome (AIDS) were described in homosexual 
men in the US in 1981. Several years later in 1983 and 1984, respectively, French and American 
scientists confirmed that the causative agent for AIDS was a retrovirus, the human 
immunodeficiency virus (Wainberg and Jeang, 2008).  
 
HIV disease is characterized by a gradual deterioration of immune function. During the typical 
course of infection crucial immune cells called CD4+ T cells (or “T-helper cells”) are disabled 
and killed. Several mechanisms of CD4+ T cell killing have been observed in lentivirus systems 
in vitro and may explain the progressive loss of these cells in HIV-infected individuals (Benito, 
2008). Increased T cell turnover and chronic immune activation play important roles in a host’s 
failure to maintain CD4+ T-cell homeostasis. Upregulation of tumor necrosis factor alpha, Fas 
ligand, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), as well as increased 
sensitivity of CD4+ T cells to death ligand-mediated apoptosis, contributes to the demise of 
uninfected CD4+ T cells (Zhou et al., 2008). HIV both destroys the cells it infects and reduces the 
body’s ability to produce new cells (McCune, 2001).  
 
A healthy, uninfected person usually has 800 to 1 200 CD4+ T cells per µl of blood. During HIV 
infection, the number of these cells in a person’s blood progressively declines. When a patient’s 
CD4+ T cell count falls below 200 cells/µl, the patient becomes particularly vulnerable to the 
opportunistic infections and cancers that typify AIDS, the end stage of HIV disease. People with 
AIDS often suffer infections of the intestinal tract, lungs, brain, eyes and other organs, as well as 
debilitating weight loss, diarrhea, neurologic conditions and cancers such as Kaposi’s sarcoma 
and lymphomas (McCune, 2001). 
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1.1.2 
 
Distribution and grouping of HIV 
Since 1986, it has been recognized that there are two strains of the virus; HIV-1 and HIV-2. They 
differ in their genome and in their infectivity, with HIV-1 being well over three times as infective 
as HIV-2. The latter infection also takes longer to cause disease. HIV-2 infections are mostly 
found in Western Africa and, increasingly, in India; HIV-1 is endemic in the rest of the world. In 
addition, HIV-2 is not as easily transmitted perinatally as HIV-1. HIV-1 is the major cause of 
AIDS in humans and, therefore, has been used as the prototype in the majority of studies on HIV 
(Gilbert et al., 2003). 
 
Considerable effort has been spent collecting and comparing nucleotide sequences of HIV 
isolates from around the world (Myers et al., 1994). This information has been used to infer the 
molecular epidemiology of the virus. The earliest phylogenetic trees of HIV revealed two clusters 
of HIV-1; North American/European isolates and African isolates. Later, analyses that included 
isolates from Thailand revealed yet another HIV-1 cluster spreading rapidly in the Northern part 
of the country (McCutchan et al., 1992). With the sequencing of additional HIV-1 isolates from 
around the world, two major groups have been identified, as shown in Figure 1.1.  
 
Viruses of group M (for "main") are responsible for the majority of infections worldwide; group 
O (for "outgroup") is a relatively rare group found in Cameroon, Gabon, and France. This group 
is, however, minimal compared to the various subtypes of group M, as was investigated by 
Brennan et al. (2008) who found that only 2.2% of the infections was attributed to group O. 
Group M can be divided into at least eight distinct subtypes or clades; A through H. Thus, 
variation in HIV-1 sequences is not continuous over a spectrum, but instead appears to cluster 
into discrete groupings (Figure 1.1). Isolates of HIV-1 from different clades may differ by 30-
40% in the amino acid sequence of the gp120 surface (SU) protein; isolates within a clade vary 
from 5-20%. It is not clear whether this pattern has resulted from multiple introductions of virus 
into humans or from discrete pathways of evolution or adaptation after the virus entered the 
human population (Myers et al., 1994; Louwagie et al., 1995).  
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Figure 1.1:  Genetic subtypes of HIV-1. A phylogenetic tree of (A) gag (MA) sequence and (B) envelope (the 
V3 portion of SU), constructed maximum likelihood, shows the prevalent genetic subtypes 
comprising the global pandemic. The subtypes are approximately equidistant and exhibit an intra-
subtype variability that is approximately one half of the inter-subtype distance. The majority of 
isolates studied to date belong to genetic subtypes A through J, making up the M (for main) group; 
a few isolates belong to the highly divergent group O (for outgroup). The clustering of the 
subgroup is identical for env and gag in all subgroups, except E (colour) where the isolates are 
clustered separately from all others in env, but cluster with subgroup A viruses in gag, implying 
that this subgroup arose by a relatively recent recombination event. Recombinants, with mosaic 
genomes combining genetic material from two or more HIV-1 subtypes, are known to occur at 
appreciable frequency in geographic locales where multiple subtypes co-circulate [Taken from 
Myers et al., 1995]. 
 
Given the extensive replication of HIV in infected individuals (Ho et al., 1995 and Wei et al., 
1995) and the substantial number of errors made during retroviral replication, it is not surprising 
that extensive viral sequence heterogeneity can emerge within a single individual (Saag et al., 
1988). Within the env gene, specific hyper variable sites occur interspersed among more 
conserved sequences, apart from genetic changes which can be observed throughout the genome. 
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Among HIV gene products, the envelope protein will therefore contain variable as well as 
conserved regions (Kong et al., 2008). These hyper variable regions are not likely to reflect sites 
of frequent errors; rather, they are likely to be regions where change can be tolerated or where 
mutations confer selective advantage. Variation in env accounts for much of the differences 
among the isolates (Fisher et al., 1988). These are most likely antigenic variants selected by the 
immune response of the host and/or variants selected for different cell tropism (Coffin et al., 
1997).  
 
1.1.3 
 
Epidemiology 
At the end of the year 2007 the estimated number of people living with HIV was 33.2 million, of 
which 30.8 million were adults, 2.5 million were children (under the age of 15 years) and almost 
23 million living in sub-Saharan Africa. The estimated number of people that were newly 
infected with HIV (in 2007) was 2.5 million, of which 2.1 million were adults, 420 000 were 
children (under the age of 15 years) and 1.7 million were from sub-Saharan Africa. The estimated 
number of deaths from AIDS in the year 2007 was 2.1 million, of which 1.7 million were adults, 
330 000 were children (under the age of 15 years) and once more the majority (1.6 million) of 
deaths occurred in sub-Saharan Africa (www.unaids.org 27 November 2007). 
 
1.1.4 
 
Transmission 
HIV is transmitted by direct sexual contact, either homosexual or heterosexual; by blood or blood 
products; and from an infected mother to infant, either intrapartum, perinatally, or via breast 
milk. HIV has been found at low concentrations in the saliva, tears and urine of infected 
individuals, but there are no recorded cases of infection by these secretions and the potential risk 
of transmission is negligible. There is also no evidence that HIV can be transmitted by casual 
contact or that virus is spread by bites of insects such as mosquitoes (Fauci and Lane, 1991).  
 
Virus must enter the body as either cell-free virions or infected cells. The mode of transmission 
(either through mucosal surfaces or by direct inoculation into the blood) generally determines the 
initial cells that the virus encounters. Despite this difference, there is no reason to believe that the 
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route of transmission alters the subsequent course of HIV infection; although it would be 
expected (and has been shown experimentally with SIV) that blood-borne transmission would be 
much more efficient (Wike et al., 1992; Clark and Shaw, 1993; Zhu et al., 1993).  
 
Likely targets for initial viral infection in the mucosa are antigen-presenting cells, particularly 
macrophage-related cells of the dendritic cell lineage. Cells residing at the mucosal surfaces are 
called Langerhans cells; those in the circulation are known as blood dendritic cells. These cells 
express CD4 as well as an appropriate co-receptor and can be infected by HIV. Infected cells are 
then transported to the lymphoid tissue where released virus can come into contact with 
susceptible CD4+ T cells that predominantly reside in the paracortical areas. Infection is thereby 
established and the subsequent burst of viremia seeds virus throughout the lymphoid tissues of 
the body (Fauci, 1993). 
 
1.1.5 
 
Attachment and entry of the virus into CD4+ T-cells 
The HIV-1 envelope regulates the initial attachment of viral particles to target cells through its 
association with CD4 and either CXCR4 or CCR5. Although F-actin is required for CD4 and 
CXCR4 redistribution, little is known about the molecular mechanisms underlying this 
fundamental process in HIV infection (Barrero-Villar et al., 2009).  
 
HIV binds to the CD4+ T-cell through gp120, after which the envelope undergoes a structural 
change, exposing the chemokine binding domains of gp120 and allowing them to interact with 
the target chemokine receptor. This allows for a more stable two-pronged attachment, which 
allows the N-terminal fusion peptide gp41 to penetrate the cell membrane and the HIV RNA and 
various enzymes including reverse transcriptase, integrase and protease are injected into the cells 
(Chan and Kim, 1998; Wyatt and Sodroski, 1998).  
 
Heptad repeat sequences in gp41, HR1 and HR2 then interact, causing the collapse of the 
extracellular portion of gp41 into a hairpin. This loop structure brings the virus and cell 
membranes close together, allowing fusion of the membrane and subsequent entry of the viral 
capsid (Chan and Kim, 1998; Wyatt and Sodroski, 1998).  
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1.1.6 
 
Replication and transcription of HIV 
The HIV is then stabilized by copying its RNA into DNA and inserting it into the cell’s 
chromosomes (Figure 1.2). This means the virus can perform more subtle functions by using the 
host transcription machinery (Mandell et al., 2004). 
 
The reverse transcriptase enzyme plays an essential role in the HIV-1 life cycle by converting a 
single-stranded viral RNA genome into a double-stranded viral DNA through a complex process 
known as reverse transcription. The resulting double-stranded DNA is integrated into the host 
chromosome to form a provirus (Mbisa et al., 2009). This process of reverse transcription is 
extremely error-prone and it is during this step that mutations may occur, which may cause drug 
resistance. If the process succeeds however, the pro-viral DNA must then be integrated into the 
host cell DNA using the integrase (IN) enzyme. If the pro-viral DNA becomes integrated into the 
host cell’s DNA the cell is now fully infected but not actively producing HIV proteins. This is the 
latent stage of HIV infection, during which the infected cell can be an “unexploded bomb” for 
potentially a long time (Zheng et al., 2005). 
 
To actively produce virus, certain transcription factors need to be present in the cell. The most 
important is NF-κB (Nuclear Factor Kappa B) and is present once the T cells become activated 
(Hiscott et al., 2001). The production of the virus is regulated. Initially the integrated pro-virus is 
copied to mRNA which is then spliced into smaller regions. These small regions produce the 
regulatory proteins tat (which encourages new virus production) and rev. As rev accumulates it 
gradually starts to inhibit mRNA splicing. At this stage the structural proteins gag and env are 
produced from the full-length mRNA. Additionally the full-length RNA is actually the virus 
genome, so it binds to the gag protein and is packaged into new virus particles. HIV-1 and HIV-2 
package their RNA differently; HIV-1 will bind to any appropriate RNA whereas HIV-2 will 
preferentially bind to the mRNA that was used to create the gag protein (Pollard and Malim, 
1998). 
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Figure 1.2:  HIV-1 life cycle. After binding and fusing to the surface of the host cell, the HIV-1 core enters the 
host cell. Reverse transcriptase synthesizes proviral double-stranded DNA, which is transported to 
the nucleus. Integration occurs and the ensuing provirus expresses viral RNA that will synthesize 
viral proteins using the host’s ribosomes. New virions are created by assembly and budding 
through the infected cell membrane and subsequent maturation due to the actions of protease. Vpr 
(viral protein R), Vpu (viral protein U), Nef (negative regulatory factor), Rev (regulator of virion 
protein expression), SU (surface), TM (transmembrane), Gag (group-specific antigen), IN 
(integrase), RT (reverse transcriptase), NRTIs (nucleoside reverse transcriptase inhibitors) and 
NNRTIs (non-nucleoside reverse transcriptase inhibitors) [Taken from Turner and Summers, 
1999].  
 
1.1.7 
 
Assembly and release of HIV 
The virus starts to form under the cell membrane, in special cholesterol-rich regions, and 
gradually buds outside. The env polyprotein (gp160) goes through the endoplasmic reticulum and 
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is transported to the Golgi complex where it is cleaved by HIV protease and processed into the 
two HIV envelope glycoproteins gp41 and gp120. These are transported back to the plasma 
membrane of the host cell where gp41 anchors the gp120 to the membrane of the infected cell. 
The gag (p55) and gag-pol (p160) polyproteins also associate with the inner surface of the 
plasma membrane along with the HIV genomic RNA as the forming virion begins to bud from 
the host cell (Gelderblom, 1997). 
 
Maturation either occurs in the forming bud or in the immature virion after it buds from the host 
cell. Maturation of the virion is necessary for it to be infectious.  During maturation the viral 
protease (PR) cleaves gag into several smaller proteins (matrix, capsid, p2, nucleocapsid, p1 and 
p6). The virus is then able to infect more cells (Gelderblom, 1997). 
 
1.1.8 
 
Course of HIV disease 
Infection of humans with HIV-1 causes a dramatic decline in the number of CD4+ T 
lymphocytes. When the number of these cells becomes low enough, opportunistic infections and 
neoplasms occur. Neurologic abnormalities, which occur in a majority of HIV-infected 
individuals, can be observed in the absence of other clinical manifestations (Pantaleo et al., 
1993). 
 
The course of the disease consists of several stages. 
 
 
Primary infection 
Primary infection of humans with HIV-1 is associated with an acute mononucleosis-like clinical 
syndrome which appears approximately 3-6 weeks following infection. Significant declines in the 
levels of CD4+ T lymphocytes in the peripheral blood occur in the first 2-8 weeks following HIV-
1 infection (Gaines et al., 1990). These levels may rebound toward normal as the patient enters 
the clinically latent stage of disease (Figure 1.3); however, they rarely if ever return to 
preinfection levels.  
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The acute syndrome associated with primary HIV-1 infection is accompanied by a burst of viral 
replication that can be detected in the blood approximately 3 weeks following infection. During 
this period, infectious virus and viral proteins can be readily detected in the cell-free plasma as 
well as in cerebrospinal fluids, and the number of virions in cell-free plasma can reach 106 to 107 
per milliliter (Clark et al., 1991, Daar et al., 1991; Tindall and Cooper, 1991). 
 
 
 
Figure 1.3:  Typical course of HIV infection. Patterns of CD4+ T-cell decline and virus load increase vary 
greatly from one patient to another, as do the actual values of viral RNA load [Taken from 
Pantaleo et al., 1993]. 
 
Approximately 3-6 weeks after the infection specific antiviral immune responses can be detected 
(Dalmau et al., 2008). These antiviral immune responses are associated with a precipitous decline 
in plasma viremia and plasma antigenemia, a decline in the viral burden, resolution of the clinical 
syndrome, and a temporary stabilization of the number of CD4+ T cells. Both humoral and 
cellular immune responses can be detected. Multiple factors probably contribute to the decline in 
viral titer, including the responses of the two arms of the immune system, the secretion of virus-
suppressing cytokines, and the possible exhaustion of suitable CD4+ target cells (Phillips, 1996). 
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Studies have indicated that the initial decline in plasma viremia is associated with the appearance 
of HIV-specific, CD8+ cytolytic T cells, whereas the first neutralizing antibody is not detected for 
several additional weeks. The vast majority of infected individuals develop detectable antibody 
responses within 3 months of infection (Koup et al., 1994).  
 
 
Clinical latency (The HIV steady state) 
Following the induction of an immune response to HIV-1 in humans, there is usually a relatively 
long period that is characterized by few, if any, clinical manifestations. When present, clinical 
symptoms are usually mild. Estimates for the average time from infection with HIV-1 to the 
development of the clinical conditions that define AIDS vary from 8 to 12 years. The time 
interval from infection to development of opportunistic disease varies greatly from one individual 
to another; however, the estimated time has gradually increased since AIDS was first recognized 
(Lemp et al., 1990a). This may be due both to better detection of infection and to antiretroviral 
therapies and effective prophylaxis for life-threatening opportunistic infections. Throughout the 
latent period, there is usually a steady decline in the numbers of CD4+ lymphocytes (Lemp et al., 
1990b, Lemp et al., 1992, Seage et al., 1993).  
 
Although the long-term asymptomatic phase can be called clinical latency, there are numerous 
clear lines of evidence to show that there is continual, rapid viral replication in the progression to 
disease. Sequence changes occur in the viral genome at a rate of about 1% per year in env; the 
only way this can occur is through continued viral replication (Balfe et al., 1990, Burns and 
Desrosiers, 1991, Simmonds et al., 1991). Antibody responses to HIV-1 are strong, and remain 
high for years, indicating constant antigenic stimulation. Virus can be recovered and/or detected 
month after month, year after year from peripheral blood cells of most infected individuals. 
Furthermore, the level of virus is remarkably constant, exhibiting relatively small day to day 
fluctuations, increasing only gradually during the course of infection. Simple modeling suggests 
that this relatively stable viral load reflects both a constant rate of new infection and death of the 
infected cells throughout most of the course of the infection (Coffin, 1995).  
 
It is not well understood how the balance between the production and clearance of virus and 
infected cells is maintained for such a long period of time. Two general mechanisms can be 
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envisioned. In the first, the host immune response keeps the virus under control but is unable to 
completely clear it. In the second, viral replication is limited by the availability of suitable 
targets, particularly activated CD4+ T cells.  
 
In the majority of infected individuals, the apparent steady state gradually breaks down, leading 
to the low numbers of CD4+ T cells and high viral loads characteristic of AIDS. All of the 
available evidence indicates that disease progression is directly linked to viral load and to the 
extent of viral replication (Cao et al., 2009).  
 
 
Clinically apparent disease 
After months to years of a continuous, yet variable, decline in the number of CD4+ T cells, the 
level of these cells drops from a normal range of 600 1200 to below 500 cells/µl. A number of 
the conditions that define AIDS as a disease are associated with the level of CD4+ T cells. At 
about 500 cells/µl, the first symptoms appear in the HIV-infected patient. Once the CD4+ T-cell 
count falls below 200 cells/µl, the patient is susceptible to AIDS-defining opportunistic infections 
and neoplasms. The decline in the level of CD4+ T cells typically continues until virtually all 
such cells are lost (Cheng-Mayer et al., 1988; Tersmette et al., 1989). 
 
1.2 
 
HIV: The virus 
1.2.1 
 
The virus structure 
The HIV (Figure 1.4) contains two identical copies of a positive sense single-stranded RNA 
strand about 9 500 nucleotides long (with nine open reading frames for 15 proteins). These may 
be linked to each other to form a genomic RNA dimer. The RNA dimer is in turn associated with 
a basic nucleocapsid (NC) protein, p9/6 (Cann, 1997). 
 
The viral genome and replicative enzymes of the human immunodeficiency virus are encased in a 
shell consisting of assembled mature capsid protein (CA), p24 (Momany et al., 1996). The capsid 
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also contains many cell derived macromolecules including tRNALys3 used as a primer during 
reverse transcription. It also includes the proteins integrase and reverse transcriptase. Surrounding 
the capsid is a layer of matrix protein (MA), p17. MA plays an important role in keeping the 
integrity of the virion particle. 
 
 
 
Figure 1.4: Schematic representation of the structure of HIV-1 [Cann, 1997].  
 
This matrix protein is associated with a bilayer or envelope, which is composed of two layers of 
phospholipid derived from the membrane of a human cell when a newly formed virus particle 
buds from the cell. Embedded in the viral envelope are proteins from the host cell and about 70 
copies of the HIV protein gp120/41 that protrudes through the surface of the virus particle (Chan 
et al., 1997). The major HIV protein associated with the envelope is thus gp120/41. This 
functions as the viral antireceptor or attachment protein. gp41 traverses the envelope, gp120 is 
present on the outer surface and is noncovalently attached to gp41. gp120 is easily shed from the 
virus particle. There are a large number of sugar chains on gp120 (which may pose a problem for 
a vaccine) (Cann, 1997).        
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The components of HIV can simply be described in the following way (Figure 1.5). The surface 
structures include the viral membrane, which is host-derived and the surface glycoprotein. A 
single polypeptide gp160 is encoded by the env gene, and after translation gp160 is cleaved to 
form gp120 (SU) and gp41 (TM), by a host enzyme in the Golgi apparatus, since it gets to the 
cell membrane via the exocytic pathway (Welman et al., 2008). 
 
 
 
Figure 1.5:  Genomic organization of HIV-1. The upper diagram represents the approximate 10 kb provirus, 
bordered by long terminal repeats (LTR) and encoding the genes for the structural proteins (GAG); 
enzyme cassette (POL); viral infectivity factor (VIF); viral proteins R and U (VPR and VPU, 
resp.); envelope proteins (ENV), including the surface (SU) and transmembrane (TM) 
glycoproteins; and so-called negative factor (NEF). The gene for the regulator of splicing and 
nuclear transport, REV, overlaps ENV. Rev acts on the cis element, Rev responsive element (RRE) 
near the end of ENV. The gene for the transactivator protein, TAT, also overlaps ENV. Both TAT 
and REV are generated from multiply spliced mRNAs. Env is generated from a singly spliced 
mRNA and GAG and GAG/POL are generated from full-length viral mRNA. The lower panel 
represents the polyproteins encoded by GAG and POL. The Gag polyprotein, which includes the 
matrix (MA), capsid (CA), nucleocapsid (NC) and p6 proteins is produced in approximately 95% 
of all translation events from full-length viral mRNA. In 5% of translations, a -1 frameshift occurs, 
resulting in synthesis of a long Gag/Pol polyprotein, which additionally produces the aspartic 
proteinase (PR), reverse transcriptase (RT) and integrase (IN) proteins. PR is responsible for 
cleaving both Gag and Gag/Pol polyproteins into the constitutive protein species as a final step in 
the virus maturation process (Beck et al., 2002).  
 
The internal structure includes the internal structural proteins, which are all encoded by the gag 
gene (group-specific antigen). p17 lines the inner surface of the viral membrane to which it is 
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attached by covalently bound myristic acid. Other proteins associated with the nucleocapsid 
include p24 and p9 (Cann, 1997).  
 
The group-specific antigen is made as a polyprotein and is cleaved after budding of the virus by a 
virally-encoded protease encoded by the pol gene. Other internal proteins encoded by the pol 
gene (polymerase) are enzymes that participate in integration and replication; reverse 
transcriptase and integrase (Freed, 2001). 
 
The genome of HIV is about the same size as any other retrovirus, for example, Rous sarcoma 
virus (RSV). However, the genome of HIV is more complex than RSV, since it has extra open 
reading frames that clearly code for small proteins. Some of these are protein synthesis-
controlling proteins. The gag gene and the gag/pol genes together are translated into 9 large 
proteins. The gag polyprotein is cleaved into four proteins that are found in the mature virus; 
matrix (MA), capsid (CA), nucleocapsid (NC) and p6. The pol polyprotein is cleaved to form 
protease (PR), reverse transcriptase (RT) and integrase (IN). The env polyprotein is translated to 
a polyprotein gp160, which is then cleaved to SU (gp120) and TM (gp41) by a host cell protease 
in the Golgi body (Freed, 2001). 
 
In addition to the nine proteins derived from gag, pol and env (which are all needed to make the 
structural proteins for new virus particles), there are six other proteins made by HIV, which are 
all proteins that control the ability of HIV to infect cells, produce new copies of virus (replicate) 
or cause disease. Three of these are incorporated into the virus (vif, vpr and nef) while the others 
are not found in the mature virus. Tat and rev are regulatory proteins and vpu assists indirectly in 
assembly. The genes that encode these proteins are known as tat (trans-activator of transcription), 
rev (regulator of virion protein expression), nef (negative regulatory factor), vif (virion infectivity 
factor), vpu (viral protein U) and vpr (viral protein R) (Freed, 2001). These genes overlap with 
the structural genes (especially env), but are in different reading frames. Some are encoded in two 
exons (unlike the structural genes) and therefore their mRNAs can be derived by alternative 
splicing of structural gene mRNAs. This is rather important to the way in which the levels of 
these are controlled. Mutations in the tat and rev genes show that both proteins they code for are 
necessary for virus production (Muesing et al., 1985; Kim et al., 1989).  
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The rate of transcription of the HIV viral genome is mediated by the interaction of the viral 
protein Tat with the long terminal repeats and other transcriptional machinery (Van Duyne et al., 
2008). Rev binds to an element present only in the mRNA for structural proteins (gag/pol/env) 
and regulates the ratio of GAG/POL/ENV to non-structural, controlling protein (TAT/REV) 
synthesis. When REV levels are high, structural protein synthesis rises and controlling protein 
synthesis falls. Thus rev inhibits its own production and that of tat. The normal result is 
homeostasis, low or non-existent virus production and latency in the resting CD4 cell. There is an 
inherent problem in HIV’s life cycle. It uses genomic RNA as its messenger RNA. This RNA is 
unspliced and the nucleus has a mechanism to prevent unspliced mRNAs from leaving the 
nucleus and being translated. It is the function of rev to overcome this problem (Thomas et al., 
1998). 
 
Nef (negative factor) protein is synthesized early in infection, and is necessary for the virus to 
replicate efficiently. It ensures T-cell activation and the establishment of a persistent state of 
infection. Nef has a positive effect on viral infection and replication by promoting the survival of 
infected cells. Its role in HIV persistence is based largely on the ability of nef to downmodulate 
the surface levels of important molecules at the immune synapse. These include major 
histocompatibility complex-I (MHCI) and MHCII present on antigen-presenting cells (APCs) and 
target cells, and CD4 and CD28 present on helper T cells. Virus produced in the presence of nef 
is little more infectious than virus produced in its absence. The translation of the nef gene as a 
result of the first infecting virus causes the internalization of CD4 antigen from the cell surface 
and its destruction in lysosomes (Das and Jameel, 2005).   
 
1.3 
 
HIV-1 protease 
HIV-1 protease is a homodimeric aspartyl protease, which is crucial for proper maturation of the 
infectious virion (Meek and Dreyer, 1990). Because HIV-1 protease is essential for maturation of 
the virus particles, it is an attractive target for antiviral drugs. The function of this protease 
depends on the dimerization of two identical subunits. Commonly used protease inhibitors are 
directed mainly against the active site of the enzyme, which often leads to viral resistance 
(Adamson and Freed, 2008). 
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1.3.1 
 
Functions of HIV-1 protease 
The gag and pol genes of HIV-1 are translated as two polyproteins, Pr55gag and Pr160gag-pol 
(Jardine et al., 2000). The two polyproteins are subsequently cleaved by the virus-encoded 
protease into the four structural gag-encoded proteins of the virion core (p17, p24, p7 and p6) 
(Freed, 2001) and the pol-encoded enzymes essential for retrovirus replication (protease, reverse 
transcriptase, ribonuclease H and endonuclease). Mutational inactivation of the protease of HIV-1 
will result in immature, non-infectious virions (Meek et al., 1990). 
 
1.3.2 
 
Structure of HIV-1 protease 
HIV-1 protease is a symmetrically arranged homodimeric protein composed of two chemically 
identical subunits of 99 amino acids each (11 kDa). The position of each monomer in the active 
protease forms an axis of symmetry. The secondary structure of each monomer includes one α-
helix, and two antiparallel β sheets. The antiparallel β sheets comprising residues 46-56 from 
both subunits form a flexible ‘flap’ region that is thought to fold down over the active site during 
catalysis to both bind substrate and exclude water (Shao et al., 1997). 
 
Aliphatic residues stabilize each monomer in a hydrophobic core. Additionally, the dimer is 
stabilized by noncovalent interactions, hydrophobic packing of side chains and interactions 
involving the catalytic residues. Each monomer contains two cysteine residues, but these do not 
form disulfide bonds. The active site forms at the dimer interface (Figure 1.6). It is created in a 
cleft between the two domains as part of a four stranded β turn (Wallqvist et al., 1998). Protein-
protein interactions in the dimer include interactions between the catalytic triad residues (Asp25 to 
Gly27), Ile50 and Gly51 at the tip of the flaps, and the antiparallel β sheets formed by the four 
termini in the dimer (residues 1-5 and 95-99). Additional interactions include a complex salt 
bridge between Asp29 and Arg87 of one subunit and Arg8 of the other subunit (Sluis-Cremer and 
Tachedjian, 2002).   
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Figure 1.6: Two experimentally determined conformations of HIV-PR. (A) Free HIV-PR with semi open 
conformation of flaps. (B) Inhibitor-bound HIV-PR with closed flaps. Importantly, the handedness 
of the flaps changes in the two forms and is depicted above each structure. Colour indicates distinct 
regions. Flaps: residues 43-58, red for free and blue for bound; flap tips: residues 49-52, yellow; 
flap elbow: residues 37-42, magenta; cantilever: residues 59-75, green; fulcrum: residues 10-23, 
orange; and interleaved-strand motif forming the dimer interface: residues 1-4 and 96-99, 
blue/cyan [Hornak et al., 2005].     
 
Asp25 from each monomer holds a water molecule by forming hydrogen bonds. Asp25 and water 
induce a general acid/base protein hydrolysis. Asp25 acts as an acid as it donates a proton to the 
carbonyl oxygen of the substrate, and acts as a base to accept a proton from the water molecule. 
19 
 
A nucleophilic attack of the water molecule results in proteolysis of the substrate (Figure 1.7). No 
covalent bonding is involved (Silva et al., 1996). 
 
 
 
Figure 1.7:  Catalytic mechanism of HIV-1 PR. (1) Binding of HIV-1 protease to a peptide substrate; (2) 
Attack of the carbonyl of the scissile amide by HIV-1 protease activated water; (3) Cleavage of the 
scissile bond; (4) Final product [Silva et al., 1996]. 
 
The mobile flap contains three characteristic regions; side chains that extend outward (Met46, 
Phe53), hydrophobic chains extending inward (Ile47, Ile54) and a glycine rich region. Ile50 remains 
at the tip of the turn. A water molecule binds to Ile50 from the interior of the cleft when the 
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protein is unliganded (Rose et al., 1998). This water plays a role in the opening and closing of the 
flaps as well as increasing the affinity between enzyme and substrate (Okimoto et al., 2000). 
 
The tips of the flaps, the glycine rich region, are highly flexible. This is thought to be necessary 
for substrate binding and product release. A curling-in movement of the flap forms a hydrophobic 
cluster as the tips are buried against a hydrophobic wall inside the cleft. The tips curl into the 
cleft resulting in an open space wide enough for a substrate to enter. Upon curling, the 
electronegative active site is exposed. Given the electronegative active site in combination with 
hydrophobic walls, a neutral or positively charged substrate could potentially be guided into a 
conformation optimal for binding (Scott and Schiffer, 2000).   
 
Protease undergoes substantial conformational changes as the cleft of the active site tightens 
around a substrate. Together, the two flap regions of protease secure the substrate within the 
binding cleft. The substrate is held rigidly in place by the flaps in order to cause proper cleavage. 
The residues in the protease cleft provide pockets into which the side chains of the substrate 
extend. The substrate binds in an extended β-sheet conformation along this cleft (hydrophobic, 
charged) through extensive hydrogen and van der Waals bonding. Thr26 of the active site remains 
shielded from the substrate interaction. The basis of substrate recognition is thought to involve 
the interactions of at least six subsites within the cleft, three subsites being contributed from each 
monomer (Weber et al., 1989). 
 
Hydrophobic subsites closest to the scissile bond have been shown to determine substrate 
specificity (Short et al., 2000). Residues Pro81, Val82 and Ile84 form the binding pocket. The 
recognition subsites are identical in each monomer, yet the amino acids on each side of the 
scissile bond are not (Wlodawer and Erickson, 1993). 
 
1.4 
 
HIV-1 integrase 
HIV integrase is a 32 kDa polypeptide that directs a defined set of DNA cleavage and joining 
events to insert the pro-viral DNA into the host genome. Both the enzymes reverse transcriptase 
and integrase are part of the viral preintegration complex (PIC), which also contains the viral 
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nucleic acids in association with nucleocapsid, matrix, p6 and viral protein R proteins (Tasara et 
al., 2000).  
 
1.4.1 
 
Functions of HIV-1 integrase 
Replication of retroviruses depends on the integration of a double-stranded (ds) DNA copy of the 
retroviral genome into the host cell nuclear genome. Integration requires integrase and DNA 
sequences located in the U3 and U5 regions at the ends of the viral long terminal repeats 
(Caumont et al., 1999). Since integrase is essential for productive retroviral infection, the enzyme 
is a potential target for antiviral chemotherapeutic intervention.  
 
The integration reaction proceeds in three steps (Figure 1.8): 
 
(1) 3’-processing: Two nucleotides (GT) from the 3’-ends of each strand of linear viral DNA are 
removed by integrase leaving at the viral 3’-ends the conserved CA  
dinucleotide (a highly conserved feature of all retroviruses) 
(2) Strand transfer: This second step is a concerted cleavage ligation reaction during which 
integrase makes staggered cuts in the target DNA and ligates the recessed 3’-
OH ends of the viral DNA to the overhanging 5’-phosphate ends of the 
target DNA at the cleavage site. The product of this reaction is a gapped 
intermediate. 
(3) 5’-joining: In the last step the integration process is completed by removal of the two 
unpaired nucleotides at the 5’-ends of the viral DNA and repair of the gaps 
between the viral and target DNA sequences. 
 
1.4.2 
 
Structure of HIV-1 integrase 
Integrase has 288 residues that fold into three domains, the N-terminal, C-terminal and core 
domains (Thomas and Brady, 1997).  
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Figure 1.8:  DNA cutting and joining steps in retroviral integration. A, the viral DNA made by reverse 
transcription is linear and blunt ended. B, in the first step of the integration process (3’-end 
processing) two nucleotides are cleaved from each 3’-end of the viral DNA. C, in the next step 
(DNA strand transfer) the hydroxyl groups at the 3’-ends of the processed viral DNA attack a pair 
of phosphodiester bonds in the target DNA. D, the resulting integration intermediate is redrawn to 
clarify the connections between viral and target DNA. Completion of DNA integration requires 
removal of the two unpaired nucleotides at the 5’-ends of the viral DNA, filling in the single strand 
gaps between host and viral DNA by a DNA polymerase, and finally ligation [Taken from Craigie, 
2001]. 
 
The N-terminal domain of HIV-1 integrase (residues 1-49, Figure 1.9B) contains a conserved pair 
of His and Cys residues, a motif similar to the zinc-coordinating residues of zinc fingers. 
Although this domain does indeed bind zinc (Burke et al., 1992; Zheng et al., 1996), its structure 
(Lodi et al., 1995) is totally different from that of zinc fingers. It consists of a bundle of three α-
helices (Lodi et al., 1995; Eijkelenboom et al., 1995). The function of the N-terminal domain is 
still unknown. 
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The C-terminal domain of HIV-1 integrase (residues 213-288, Figure 1.9C) binds DNA non-
specifically. Because the sites of integration into target DNA are relatively non-specific, it has 
been suggested that this domain may interact with target DNA. However, experiments with 
chimeric integrases (Katzman and Sudol, 1995; Shibagaki and Chow, 1997) assigned recognition 
of the target site to the core domain, and cross-linking studies (Esposito and Craigie, 1998; 
Jenkins et al., 1997; Heuer and Brown, 1997; Heuer and Brown, 1998) suggest that the C-
terminal domain interacts with a subterminal region just inside the very ends of the viral DNA. 
The C-terminal domain of retroviral integrases may therefore play a similar role to that of the 
site-specific DNA binding domain of transposases, which also recognize a subterminal sequence 
at the ends of the transposon DNA (Craigie, 2001). 
 
The catalytic core domain of HIV-1 integrase (residues 50-212, Figure 1.9A) consists of a central 
five-stranded β-sheet with six surrounding helices and contains the invariant triad of acidic 
residues, the D,D-35-E motif, comprising residues Asp64, Asp116 and Glu152 (Engelman and 
Craigie, 1992; Kulkosky et al., 1992; Polard and Chandler, 1995; Rowland and Dyke, 1990). 
Mutagenesis of these residues abolishes or severely diminishes all catalytic activities in parallel. 
The catalytic residues Asp64, Asp116 and Glu152 are in close proximity, coordinate divalent metal 
ion, and define the active site. However, the residues comprising the active site region exhibit 
considerable flexibility, suggesting that binding of DNA substrate is required to impose the 
precise configuration of residues that are required for catalysis (Craigie, 2001).  
 
In all structures to date, the quaternary structure of integrase is dimeric. However, the full 
enzyme is likely to function as at least a tetramer (Esposito and Craigie, 1999). The dimer 
interface in the catalytic core-C-terminal two domain fragment involves the strong helix-to-helix 
contacts α1 (residues 99-108): α5’ (residues 168-185) and α5: α1’, where both hydrophobic and 
electrostatic interactions contribute to dimer stabilization. In the N-terminal-catalytic core two 
domain structure, additional subunit interface interactions are provided from the N-terminal 
domain, in particular residues 29-35 (Sluis-Cremer and Tachedjian, 2002). 
 
The solution structure of the HIV-1 integrase minimal binding domain is a dimer. Each monomer 
is constructed of five β-strands that are arranged in an antiparallel orientation to form a five-
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stranded β-barrel. Interactions between two, three-stranded β-sheets occur at the interface 
between monomers. These interactions are predominantly hydrophobic (Trp243, Ala248 and Val250 
from one monomer interacting with Leu242, Val250, Ile257 and Val259 of the other). Further 
stabilization of the dimer is achieved by hydrogen bonding between the carboxylate of Glu246 of 
one monomer to the carboxamide of Gln252 of the other (Dyda et al., 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9:  Structures of the three domains of HIV-1 integrase shown as ribbon diagrams. (A) the catalytic 
core domain; (B) the N-terminal domain; (C) the C-terminal domain [Taken from Craigie, 2001]. 
 
The dimeric DNA binding domain possesses a large, saddle-shaped groove bound by loops 
connecting β-strands 1 and 2 in each monomer. The catalytic core and the DNA binding domain 
are both modeled as dimers. The separation between the C-terminal residues (Ile208’s) of each 
monomer of the catalytic domain is 21 Å. The separation between the N-terminal residues 
(Ile220’s) of the two monomers of the DNA binding domain is ~ 17 Å. With such dimensions, the 
dimerized catalytic core can be envisioned to fit directly on top of the dimerized DNA binding 
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domain in the intact protein, the two domains being connected by an 11 residue stretch missing in 
both models (Lodi et al., 1995).  
 
Despite the strong structural evidence supporting dimeric models for both the catalytic core and 
DNA binding domains, there are spatial problems to be considered. Any model of the mechanism 
with which a multimer carries out integration must be consistent with the nucleotide spacing 
between the phosphates on the two ends of each half of target DNA. This five nucleotide spacing 
requires a pair of active sites separated by approximately 15 Å. However, as discussed above, the 
active sites on a dimeric model of the catalytic core domain are separated by ~ 35 Å. Perhaps 
considerable distortion of the core domain and/or of the DNA substrate occurs upon binding 
(Lodi et al., 1995).  
 
Alternatively, it may be that dimers associate into functional tetramers. A tetrameric model 
formed by a pair of dimers could position two of the active sites within the required 15 Å. In this 
model, two active sites from separate dimers would catalyze the 3’ processing and strand transfer. 
The other two active sites would not carry out any catalysis, and would possibly serve only as 
structural components (Dyda et al., 1994). 
 
1.5 
 
Anti-HIV activity 
1.5.1 
 
Immune system response to HIV infection 
The immune system response in the presence of the HIV-1 infection includes both antibody 
development (humoral immune response) and activities of T lymphocytes (cellular immune 
response). HIV seems to be able to escape the humoral immune response in the course of the 
disease. Several studies have indicated that neutralization-resistant HIV-1 variants emerge during 
the course of infection (McMichael and Rowland-Jones, 2001). 
 
In contrast a strong cellular immune response with CD8+ lymphocytes can be detected against 
virtually all of the HIV-encoded protein products. Since CD8+ lymphocyte activity is dependent 
at least in part on help (cytokines, growth factors, etc.) from CD4+ T cells, the decline in CD8+ 
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lymphocyte activity may be related to the decline in the number (and functionality) of CD4+ T 
lymphocytes. CD8+ lymphocytes, however, fail to control HIV infection, which can be attributed 
to various strategies that HIV employs to evade the immune system. Intrinsic defects in CD8+ T 
cells themselves have also been proposed to contribute to their inability to control HIV (Petrovas 
et al., 2004).  
 
1.5.2 
 
HIV immunity and tolerance 
Disease progression is not an inevitable outcome of lentiviral infections. African green monkeys 
and sooty mangabey monkeys can be persistently infected with SIV, apparently for life, but they 
do not appear to develop any disease. SIV from these monkeys are certainly capable of causing 
disease in a different host. Although most chimpanzees infected with wild-type HIV-1 and 
macaques infected with mutants of SIV usually remain persistently infected but asymptomatic 
(Johnson et al., 1993), disease has been reported in an HIV-infected chimpanzee. The immune 
systems of these species appear to control (but not eliminate) these lentiviral infections; however, 
other as yet unidentified factors may contribute to the lack of disease. In general, it seems that in 
the natural host, the virus and the host are well adapted to each other. Such adaptations must lead 
to features that maintain a constant low virus load, transmissibility of the virus, and prevent 
evolution of more virulent variants (Novembre et al., 1997). 
 
There are well-founded reports of humans who have remained uninfected despite definite and 
regular contact with HIV (Francis et al., 1999). The most striking are the sex workers in Kenya 
where around 5% remain uninfected despite very high levels of contact (in the whole sex worker 
population around 90% are infected). It was shown that these women make CD8+ T-cell 
responses to HIV in their blood and genital mucosa. They do not make neutralising IgG antibody 
responses nor do they have the genetic polymorphisms in chemokine receptors that protect. 
Additionally their cells are fully infectible by HIV in vitro. This suggests that they are protected 
by the CD8+ T-cell response. Indeed they are not infected so this suggests that, under some 
circumstances, CD8+ T-cells can completely protect. It was subsequently shown that some of the 
women who have changed their life-styles and ceased sex work have later become infected. This 
seemed immunological, suggesting that they need regular contact with the virus to maintain their 
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protection. This might mean that it is necessary to maintain the cytotoxic T lymphocytes (CTLs) 
in a state of activation to offer best protection, something that present vaccines might not be able 
to do (McMichael et al., 2002). 
 
1.5.3 
 
Immunological approaches 
Whether neutralizing antibodies developed in the host during HIV infection have any significant 
role in suppression (or, potentially, prevention) of HIV infection is unclear. Instead, it is likely 
that the extensive glycosylation of the primate lentiviral env proteins, combined with special 
structural features, renders HIV nearly invisible to potentially neutralizing antibodies. This 
implies that immune control of HIV infection (if it can be achieved) rests with the cellular arm of 
the immune system and that for a vaccine to be effective, a focus on cellular immunity may be 
required (Varmus et al., 1997). 
 
Primate models are normally used for testing HIV vaccines (Haigwood, 2004). However, two 
possible HIV vaccines were tested in 2006, with the hope of producing an immune response in 
healthy, uninfected adults. One was a plasmid DNA-based vaccine expressing genes from three 
dominant HIV subtypes, and the second used recombinant adenovirus serotype 5 (rAd5) as a 
vector to deliver similar HIV strains. Both approaches operate by gene delivery of customized 
vaccine antigens that are produced by host cells to initiate an immune response. Both vaccines 
were tested in healthy adult volunteers, and were well-tolerated; however, the recombinant vector 
vaccine had some adverse events (such as pain and fever) with higher doses (Infectious Diseases 
Society of America, 2006).  
 
The DNA studies were a landmark for DNA-based vaccines in that they were the first to 
demonstrate a DNA vaccine successfully eliciting immune responses in essentially all vaccinated 
volunteers. According to Barney S. Graham (National Institutes of Health NIH Vaccine Research 
Center in Maryland), the next step is to evaluate the combination of DNA priming and rAd5 
boosting, as combining these distinct gene-delivery vaccination approaches has the potential to 
induce higher levels of T cell responses and a different quality of response than either approach 
by itself (Infectious Diseases Society of America, 2006).   
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 1.5.4 
 
Pharmacological treatment of HIV/AIDS 
It has been demonstrated that antiretroviral therapy administered to patients during primary HIV 
infection improves the clinical course of the disease and increases the CD4+ T-cell count 
compared to individuals who remain untreated during the period of primary HIV infection. 
Inhibitors of HIV-1 RT and PR are widely used in the clinical treatment of AIDS. However, the 
emergence of drug-resistant variants of HIV-1 severely limits the long-term effectiveness of these 
drugs. The optimization of current antiretroviral drug regimens and the development of new 
drugs are challenging issues in HIV chemotherapy (Menendez-Arias, 2002). HIV positive 
patients today are given a complex of drugs termed highly active antiretroviral therapy (HAART) 
that attack HIV at various stages in its life cycle. These antiretroviral drugs target PR, RT, IN and 
entry of the virus and are discussed below. 
 
1.5.4.1 
 
Protease inhibitors (PIs) 
Protease inhibitors bind to the active site of HIV protease and thereby prevent the processing of 
viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-
infectious viral particles (Meek et al., 1990).  
 
Examples of protease inhibitors include Crixivan (Indinavir sulfate) [Figure 1.10A], Agenerase 
(Amprenavir) [Figure 1.10B], Invirase (Saquinavir) [Figure 1.10C], Norvir (Ritonavir) [Figure 
1.10D] and Viracept (Nelfinavir) [Figure 1.10E].  
 
Protease inhibitors used in combination with RT inhibitors represent the most effective anti-HIV 
therapies developed to date. Several studies have reported that combination therapies reduce HIV 
viral load to undetectable levels for sustained periods of time in up to 90% of patients. The use of 
RT inhibitors not only results in synergism but also substantially reduces the likelihood of 
protease or multiple-resistant HIV strains developing. Monotherapy, especially low dose therapy, 
often results in the rapid emergence of protease resistant HIV strains (Campiani et al., 2002). 
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A  B  
C  D  
E  
 
Figure 1.10: HIV-1 protease inhibitors. Chemical structures of (A) Crixivan (indinavir sulfate); (B) Agenerase 
(aprenavir); (C) Invirase (saquinavir mesylate); (D) Norvir (ritonavir); (E) Viracept (nelfinavir 
mesylate) [Taken from Wlodawer and Vondrasek, 1998]. 
 
1.5.4.2 
 
Reverse transcriptase inhibitors (RTIs) 
Reverse transcriptase inhibitors block reverse transcriptase’s enzymatic function and prevent 
completion of synthesis of the double-stranded viral DNA thus preventing HIV from multiplying. 
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The process of reverse transcriptase copying the viral single stranded RNA genome into double-
stranded viral DNA is thus prevented. There are three forms of reverse transcriptase inhibitors as 
discussed below. 
 
1.5.4.2.1 
 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Non-nucleoside reverse transcriptase inhibitors (Figure 1.11) stop HIV production by binding 
directly onto reverse transcriptase, preventing RNA-dependant and DNA-dependant DNA 
polymerase activities. These drugs are called “non-nucleoside” inhibitors because even though 
they work at the same stage as nucleoside analogues, they act in a completely different way. 
 
A  B  
C  
  
Figure 1.11:   Non-nucleoside reverse transcriptase inhibitors. Chemical structures of (A) Viramune (nevirapine);  
                       (B) Sustiva (efavirenz); (C) Rescriptor (delavirdine mesylate) [Sluis-Cremer and Tachedjian, 2002]. 
 
These inhibitors block reverse transcriptase by binding at a different site on the enzyme, 
compared to nucleoside RT inhibitors (NRTIs) and nucleotide RT inhibitors (NtRTIs). They are 
not incorporated into the viral DNA but instead inhibit the movement of protein domains of 
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reverse transcriptase that are needed to carry out the process of DNA synthesis. NNRTIs are 
therefore termed non-competitive inhibitors of reverse transcriptase (De Clercq, 1996). Examples 
of NNRTIs include Viramune (Nevirapine) [Figure 1.11A], Sustiva (Efavirenz) [Figure 1.11B] 
and Rescriptor (Delavirdine) [Figure 1.11C]. 
 
1.5.4.2.2 
 
Nucleoside analog reverse transcriptase inhibitors (NARTIs or NRTIs) 
The first effective class of antiretroviral drugs was the nucleoside analogues. In order for them to 
be incorporated into the viral DNA, nucleoside analog reverse transcriptase inhibitors must be 
activated in the cell by the addition of three phosphate groups to their deoxyribose moiety, to 
form NRTI triphosphates. This phosphorylation step is carried out by cellular kinase enzymes.  
 
These inhibitors are analogs of the naturally occurring deoxynucleotides needed to synthesize the 
viral DNA and they compete with the natural deoxynucleotides for incorporation into the 
growing viral DNA chain. They, however, lack a 3’-hydroxyl group on the deoxyribose moiety, 
and as a result, following incorporation of a NRTI, the next incoming deoxynucleotide cannot 
form the next 5’-3’ phosphodiester bond needed to extend the DNA chain, and chain termination 
occurs. All NRTIs (and NtRTIs) are therefore termed competitive substrate inhibitors. The 
resulting DNA is incomplete and cannot create new virus (De Clercq, 1995a; De Clercq, 1995b).  
 
Examples of nucleoside analog reverse transcriptase inhibitors include Epivir/Lamivudine (3TC) 
[Figure 1.12A], Ziagen (Abacavir) [Figure 1.12B], Retrovir (AZT) [Figure 1.12C], Videx (ddI) 
[Figure 1.12D], Hivid (ddC) [Figure 1.12E] and Zerit (d4T) [Figure 1.12F]. 
 
1.5.4.2.3 
 
Nucleotide analog reverse transcriptase inhibitors (NtARTIs or NtRTIs) 
The mode of action of nucleoside analog reverse transcriptase inhibitors and nucleotide analog 
reverse transcriptase inhibitors is essentially the same. Normally, nucleoside analogs are 
converted into nucleotide analogs by the body. Taking nucleotide analog reverse transcriptase 
inhibitors directly allows conversion steps to be skipped, causing less toxicity. An example of a 
nucleotide analog reverse transcriptase inhibitor is Viread (Tenofovir) [Figure 1.13]. Tenofovir 
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diphosphate inhibits the activity of  HIV-1 reverse transcriptase by competing with the natural 
substrate deoxyadenosine 5-triphosphate and, after incorporation into DNA, by DNA 
termination. 
  
A  B  C  
D  E  F  
 
Figure 1.12:   Nucleoside reverse transcriptase inhibitors. Chemical structures of (A) Epivir/lamivudine (3TC); (B) 
Ziagen (abacavir sulfate); (C) Retrovir/zidovudine (AZT); (D) Videx/didanosine (ddI); (E)    
Hivid/zalcitabine (ddC); (F) Zerit/stavudine (d4T) [Taken from Graul et al., 1998].    
 
 
 
Figure 1.13:   Chemical structure of viread (tenofovir disoproxil fumarate) [www.uochb.cz/web/structure/550.html  
                       29 December 2008].   
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1.5.4.3 
 
Entry inhibitors 
Entry inhibitors block viral entry into the cell, interacting directly with the viral receptor and 
avoiding fusion of the viral membrane with the target cell membrane (Figure 1.14). Enfuvirtide 
(see below) in particular interferes with the entry of HIV-1 into cells by inhibiting fusion of viral 
and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of 
the viral envelope glycoprotein and prevents the conformational changes required for the fusion 
of viral and cellular membranes (De Clercq, 1998). Examples of entry inhibitors include 
Fuzeon/Enfuvirtide (T-20╪) [Figure 1.15], AMD-3100, FP21399 and PRO 542. 
 
 
 
Figure 1.14:  Mechanism of HIV inhibition by entry inhibitors. Enfuvirtide (T-20╪) is a 36 amino acid peptide 
derived from the extracellular domain of gp41 of the HIV-1 envelope. After gp120 binds to a CD4+ 
cell, the transmembrane (TM) domain undergoes a conformational change that includes unfolding, 
which results in the ‘spring-loaded’ formation of coiled-coil helices in preparation for viral entry. 
Enfuvirtide binds to the transmembrane domain and prevents fusion to the host cell and viral entry 
[Kilby et al., 1998]. 
 
Entry inhibitors (fusion inhibitors) are intended to protect cells from infection by HIV by 
preventing the virus from breaking through the cell membrane. These drugs are expected to be 
able to prevent infection of a cell by either free virus (in the blood) or by contact with an infected 
cell. They are given by infusion or injection. This is a newer class of anti-HIV drugs, and their 
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efficacy validates entry as a point of intervention in viral life cycles. In the context of HIV 
treatment, they also contribute to the growing armamentarium of antivirals which, in multidrug 
combinations, can effectively inhibit viral replication and prevent disease progression (Melby and 
Westby, 2009). 
 
 
 
Figure 1.15:  The chemical structure of fuzeon/enfuvirtide (T-20╪). The empirical formula of fuzeon/enfuvirtide 
is C204H301N51O64. It has the following primary amino acid sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-
Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-
Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 [www.chemblink.com
 
 29 December 2008]. 
1.5.4.4 
 
Integrase inhibitors 
Disruption of integrase activity as a means of therapy can be achieved by disrupting nuclear 
localization, dimer/multimer formation and the protein-DNA interaction, and inhibition of the 
processing and/or joining reaction. Integrase inhibitors act at the integration stage after HIV’s 
genetic code is changed from a single strand to a double strand by reverse transcriptase (Dubey et 
al., 2007). An example of an integrase inhibitor is Zintevir (AR-177).  
 
Zintevir (a 17-mer oligodeoxynucleotide) is a polyanionic substance that consists solely of 
thymine and guanine as the heterocyclic moieties and which forms two stacked G-quartets that 
can bind a potassium ion in the centre. Zintevir, as well as interfering with viral integrase, also 
interferes with the virus adsorption process (Ojwang et al., 1995). 
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1.5.4.5 
 
Antisense drugs 
These drugs are mirror images of parts of the HIV genetic code. The drug locks onto the virus 
genome to prevent it from functioning. One antisense drug, HGTV43, is in Phase I trials. 
HGTV43 carries anti-HIV-1 antisense RNA genes directed against the genes responsible for viral 
replication. HGTV43 is designed to deliver the antisense genes to targeted blood cells of patients 
infected with HIV-1. These genes are incorporated into the DNA of the subjects’ blood stem cells 
and subsequent production of the anti-HIV-1 antisense RNA is designed to prevent replication of 
the virus, providing resistance to the virus (Enzo Biochem. Annual Report, 2006). 
 
Many problems are involved in establishing a course of treatment for HIV. Each effective drug 
has side effects, often serious and sometimes life-threatening in themselves. Common side effects 
include extreme nausea and diarrhea, liver damage and failure, and jaundice. Any treatment 
requires regular blood tests to determine continued efficacy (in terms of T-cell count and viral 
load) and liver function. 
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Chapter 2 
 
Aim of the Project 
 
As Western medicine is getting less affordable to many people, interest in alternatives such as 
traditional medicine has been growing over the past few years. These medicines, however, still 
show side effects, which include liver damage (Hutchings, 1989) and metal poisoning (van 
Vonderen et al., 2000; Steenkamp et al., 2002). Therefore, more information and quality control 
is still needed. The biological activities of medicinal plants and traditional medicines prescribed 
by traditional healers for, for example HIV/AIDS, need to be evaluated. Anti-HIV medication 
can be screened in vitro for inhibition of HIV-reverse transcriptase (HIV-RT), protease, integrase 
and host-glycosidase activity, as well as for inhibition of gp120-CD4 binding. While commercial 
kits are available for drug screening of HIV-RT (Roche, Germany) and HIV-PR (Bachem, 
Switzerland), no commercial HIV-IN kit is currently on the market, nor kits for gp120-CD4 
binding. Additionally, the HIV-PR kit is prohibitively expensive for routine drug screening 
programmes. An alternative solution is therefore to prepare purified recombinant HIV-PR and 
HIV-IN for such drug screening programmes, allowing for continuous, renewable access to the 
enzymes required. 
 
The aims for this project were: 
1. To produce active recombinant HIV-1 protease. 
2. To produce active recombinant HIV-1 integrase. 
 
The recombinant enzymes could then be used for screening South African medicinal plant 
extracts for inhibitors of these HIV enzymes in future studies, and hence provide lead molecules 
that could potentially be used against HIV.  While in vitro activity against HIV enzymes does 
have merit, it must be remembered that in vivo assays against live virus is necessary prior to 
development of novel drugs derived from plant extracts. 
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Chapter 3 
 
HIV-1 Protease 
3.1 
 
Introduction 
As mentioned in Chapter 1, HIV-1 protease is an 11 kDa protein encoded by the pol open reading 
frame of the HIV-1 genome, and is responsible for an autoproteolytic release of the protease from 
the gag-pol fusion precursor protein and subsequent processing of the gag and pol proteins to 
yield viral structural proteins and important enzymes for replication (Debouck et al., 1987; 
Graves et al., 1988; Hansen et al., 1988).  
 
Previous expression in Escherichia coli (Debouck et al., 1987) and its subsequent 
characterization showed that HIV-1 protease belongs to the mechanistic class of the aspartic 
proteases (Meek et al., 1989), and that in its active form the enzyme is a homodimer (Pearl and 
Taylor, 1987; Navia et al., 1989; Wlodawer et al., 1989). HIV-1 protease is also inhibited by 
pepstatin A, a well known inhibitor to aspartic proteases (Seelmeier et al., 1988; Darke et al., 
1989). HIV-1 protease optimally catalyzes in the pH range of 4-6, in contrast to nearly all of the 
eukaryotic aspartic proteases, which catalyze best in the pH range of 2-4 (Ido et al., 1991). 
 
In order to facilitate the identification of novel inhibitors of HIV-1 protease, as well as to permit 
studies on the enzymology and inhibition of this enzyme, its proteolytic activity has been studied 
using various techniques, including protein immunoblot analysis of the gag polyprotein and its 
cleavage products (Seelmeier et al., 1988; Giam and Boros, 1988), high-performance liquid 
chromatography (Billich et al., 1988; Darke et al., 1988) and thin-layer electrophoretic analysis 
of synthetic peptide-cleavage fragments (Kotler et al., 1988). These methods, however, were all 
relatively time-consuming and impractical for screening and characterizing large numbers of 
inhibitors, as well as not being well suited for enzymological studies because continuous 
measurement of reaction kinetics were not possible (Nashed et al., 1989).  
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Fluorescence assays have since been developed where quenched fluorogenic substrates, whose 
peptide sequence is derived from natural processing sites of HIV-1 protease, are incubated with 
recombinant HIV-1 protease. This results in specific cleavage at, for example, the Tyr-Pro bond, 
and a time-dependant increase in fluorescence intensity that linearly relates to the extent of 
substrate hydrolysis (Matayoshi et al., 1990). 
 
HIV-1 protease is prepared and expressed in an Escherichia coli strain optimized for protease 
expression in the form of inclusion bodies. The HIV-1 protease can then readily be extracted 
from the inclusion bodies using gel-filtration in a denaturing buffer and refolded using dialysis or 
rapid dilution methods (Hui et al., 1993).  
 
HIV-1 protease has been expressed mainly in BL21(DE3)pLysS and ROSETTA(DE3)pLysS 
cells (supplied by Novagen, USA). In the Novagen competent cell system E. coli strains are 
available specifically for pET expression vectors (λDE3 lysogens), as well as isogenic control 
strains (non-lysogens) for protein expression applications. The host is a lysogen of λDE3, and 
carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 
promotor (Studier and Moffatt, 1986; Rosenberg et al., 1987; Studier et al., 1990). These strains 
are suitable for production of protein from target genes cloned in pET vectors. The designation 
pLysS is given to hosts carrying a pET-compatible plasmid that encodes T7 lysozyme, a natural 
inhibitor of T7 RNA polymerase (Studier, 1991; Zhang and Studier, 1997). This strain is used to 
suppress basal expression of T7 RNA polymerase prior to induction and thus stabilize pET 
recombinants encoding target proteins that affect cell growth and viability.  
 
BL21 is the most widely used host background for protein expression and has the advantage of 
being deficient in both lon and ompT proteases (Phillips et al., 1984). Rosetta host strains are 
BL21 lacZY (TunerTM) derivatives designed to enhance the expression of eukaryotic proteins 
whose transcriptors contain codons rarely used in E. coli (Kane, 1995; Kurland and Gallant, 
1996; Brinkman et al., 1989; Seidel et al., 1992; Baca and Hol, 2000). These strains supply 
tRNAs for the codons, AUA, AGG, AGA, CUA, CCC, GGA on a compatible chloramphenicol-
resistant plasmid. The tRNA genes are driven by their native promoters (Novy et al., 2001). Thus 
the Rosetta strains provide for “universal” translation which is otherwise limited by the codon 
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usage of E. coli. In Rosetta(DE3)pLysS and Rosetta(DE3)pLacI, the rare tRNA genes are present 
on the same plasmids that carry the T7 lysozyme and lac repressor genes, respectively (Novagen, 
2002).   
 
The pET vector system is based on the lac operon and is a powerful system for cloning and 
expression of recombinant proteins in E. coli. Target genes are cloned in pET plasmids under 
control of strong bacteriophage T7 transcription and translation signals. Expression is induced by 
providing a source of T7 RNA polymerase in the host cell. T7 RNA polymerase is highly 
selective for its promoter and its activity is such that, when fully induced, most of the cell’s 
resources are converted to target gene expression. Expression levels can also be attenuated by 
lowering the concentration of the inducer, which may enhance the soluble yield of some target 
proteins (Novagen, 2002). 
 
Target genes are initially cloned using hosts that do not contain the T7 RNA polymerase gene, 
thus eliminating plasmid instability due to the production of proteins potentially toxic to the host 
cell. Once established in a non-expression host, target protein expression may be initiated either 
by infecting the host with λ CE6, a phage that carries the T7 RNA polymerase gene under the 
control of the λ pL and pI promoters, or by transferring the plasmid into an expression host 
containing a chromosomal copy of the T7 RNA polymerase gene under lacUV5 control. When 
transferring a plasmid into an expression host, expression is induced by the addition of isopropyl-
β-D-thiogalactopyranoside (IPTG) to the bacterial culture. Although in some cases it may be 
possible to clone directly into expression hosts, this approach is not recommended as a general 
strategy (Novagen, 2002). 
 
Novagen transcription vectors are designed for expression of target genes that already carry their 
own prokaryotic ribosome binding site and AUG start codon. There are only three transcription 
vectors; pET-21(+), pET-24(+) and pET-23(+). Translation vectors contain the highly efficient 
ribosome binding site from the phage T7 major capsid protein and are used for the expression of 
target genes without their own ribosomal binding sites. The translation vector names are 
distinguished from the transcription vector names by the addition of a letter suffix following the 
name, e.g. pET-21a(+), which denotes the reading frame relative to the BamHI cloning site 
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recognition sequence, GGATCC. All vectors with the suffix “a” express from the GGA triplet, all 
vectors with the suffix “b” [for example pET-28b(+) that was used for the cloning of HIV-1 
protease in this project] express from the GAT triplet, and all vectors with the suffix “c” express 
from the ATC triplet of the BamHI recognition sequence. Vectors with a “d” suffix also express 
from the “c” frame, but contain an upstream NcoI cloning site in place of the NdeI site in that 
series for insertion of target genes directly into the AUG start codon (Novagen, 2002). 
 
3.2 
 
Methodology 
3.2.1 
 
Cloning the HIV-1 protease gene 
The NIH AIDS Research and Reference Reagent Program donated an HIV-1 protease gene, for 
cloning into a bacterial expression vector, to the NMMU Biochemistry and Microbiology 
laboratory. The protease gene has been cloned into a pUC18 cloning vector (between the HindIII 
and EcoRI sites) and is called pProtease. The coding sequence has also been modified to utilize 
codons favoured by yeast and E.coli and includes the N-terminal Met (Figure 3.1). 
 
3.2.1.1 
 
Plasmid purification 
Streak plates of the stock, pProtease plasmid transformed into E. coli, were made on LB/Amp 
plates. Single colonies were inoculated into 50 ml LB medium (containing 100 µg/ml ampicillin) 
and incubated overnight at 37ºC with vigorous shaking on an orbital shaker. Plasmid isolations 
were performed using the QIAGEN Mini-Prep isolation kit (Qiagen, Germany). Similarly the 
expression vector to be used, pET28b(+) (Novagen, USA), was transformed into E.coli DH5α 
cells and single colonies from spread plates were grown in 50 ml LB medium containing 15 
µg/ml kanamycin. Plasmids were purified from overnight cultures using the Qiagen Mini-Prep 
plasmid purification kit. 
 
QIAGEN plasmid purification protocols are based on a modified alkaline lysis procedure, 
followed by binding of plasmid DNA to QIAGEN anion-exchange resin under appropriate low 
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salt and pH conditions. RNA, proteins, dyes and low-molecular-weight impurities are removed 
by a medium-salt wash. Plasmid DNA is eluted in a high-salt buffer, and then concentrated and 
desalted by isopropanol precipitation.  
 
 
 
Figure 3.1:  Nucleotide sequence encoding HIV-1 protease and translated amino acid sequence of HIV-1 protease 
[www.aidsreagent.org
 
 29 December 2008]. 
3.2.1.2 
 
Restriction digestion 
The presence of the protease gene was confirmed using the restriction enzymes HindIII and 
EcoRI. These two restriction enzymes were chosen as they were the ones used to clone the 
protease gene into the pUC18 cloning vector (Figure 3.2).  
 
A typical double restriction digest reaction contained 3 U HindIII, 3 U EcoRI, 1 µl 10x Digest 
Buffer B (Roche, Germany), 5 µl isolated pProtease vector and ddH2O to make the reaction 
volume to 10 µl. This reaction mixture was incubated at 37ºC for 1 hour, after which it was 
analyzed using agarose gel electrophoresis. With agarose gel electrophoresis the number and size 
of the digested fragments, by way of a sized marker, could be determined.    
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Agarose gel electrophoresis is a simple and effective method used in the analyses of DNA 
products resulting from polymerase chain reaction amplification, DNA purification protocols or 
DNA cloning experiments. Agarose gel electrophoresis was performed using a 1% (w/v) agarose 
gel in Tris-acetate-EDTA buffer (TAE); prepared as a 50 times dilution from a stock solution 
containing 242 g Tris, 57.1 ml acetic acid and 100 ml 0.5 M EDTA at pH 8 (Sambrook et al., 
1989). The gel was prepared with 0.5 µg/ml ethidium bromide to visualise the nucleic acid 
fragments, and was run at 100V, 64mA for approximately 45 minutes. The gel was removed from 
the electrophoresis tray and viewed on a transilluminator and digital photographs were taken 
using an AlphaImagerTM 3400. 
 
 
 
Figure 3.2:  Representation of HIV-1 Protease Designer GeneTM (NIH AIDS Research and Reference Reagent 
Program donation). 
 
3.2.1.3 
 
Polymerase chain reaction 
The protease gene was amplified from the isolated pProtease vector using polymerase chain 
reaction (PCR), with a forward primer of 5’-AAGCTTACCTCATATGCCGCAAATC-3’ and 
one of two reverse primers of either 5’-CCATTCGGATCCTTACTAG-3’ or 5’-
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CCATTCGGATCC
 
TTACTAGAAG-3’. Two reverse primers were designed and implemented to 
find one that gave optimal results (optimal amplification).  
A typical PCR reaction contained 2.5 µl 10x Pfu polymerase buffer (Mg2+ included), 0.5 µl 
dNTP’s (10 mM each), 1 µl forward primer (100 pmole/µl), 1 µl reverse primer (100 pmole/µl), 
1.25 µl DMSO, 2 µl 5 x template DNA (which was heated at 95ºC for 5 minutes and placed on 
ice prior to use in the polymerase chain reaction), 1 µl Pfu polymerase (10 U/µl) and 15.75 µl 
ddH2O to make up the reaction volume of 25 µl.  
 
PCR cycles were as follows: 1 cycle of denaturation at 95ºC for 2 minutes; 30 cycles at 95ºC for 
30 seconds, 50-60ºC annealing for 45 seconds and 72ºC for 1.5 minutes extension; 1 cycle at 
72ºC for 10 minutes to polish amplicons and 1 cycle at 4ºC for 5 minutes. The resultant PCR 
fragments obtained were analyzed with agarose gel electrophoresis, and the correctly sized bands 
were purified from the gel using the QIAquick Gel Extraction Kit (Qiagen, Germany).  
 
The QIAquick system employs the selective binding properties of a uniquely designed silica-gel 
membrane. Special buffers provided with each kit are optimized for efficient recovery of DNA 
and removal of contaminants. DNA adsorbs to the silica-membrane in the presence of high salt 
while contaminants pass through the column. The adsorption of nucleic acids to silica-gel 
surfaces occurs only in the presence of a high concentration of chaotropic salts (Vogelstein and 
Gillespie, 1979), which modify the structure of water (Hamaguchi and Geiduschek, 1962). 
Impurities are efficiently washed away, and the pure DNA is eluted with Tris-EDTA buffer or 
water.     
 
3.2.1.4 
 
Purification of PCR amplicons 
The PCR products and the purified expression vector, pET28b(+) (Figure 3.3), were then 
prepared for ligation, by restriction digestion with NdeI and BamHI (see section 3.2.1.2). These 
restriction sites were incorporated during amplification of the HIV-1 protease gene. Restriction 
digests were analyzed by agarose gel electrophoresis (section 3.2.1.2) and bands obtained were 
purified from the gel (using the QIAquick gel extraction kit, see section 3.2.1.3). Purified 
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restricted DNA was used in a ligation reaction to obtain the expression vector p28bHIV1PR 
(Figure 3.4). 
 
 
 
Figure 3.3: Vector map of pET28a-c(+) [http://www.merckbiosciences.co.uk
 
 5 January 2009]. 
3.2.1.5 
 
Ligation reaction obtaining p28bHIV1PR 
Cloning into plasmid vectors entails using plasmid DNA that is cleaved with a restriction enzyme 
and joined in vitro to foreign DNA, after which the resulting plasmids are used to transform 
bacteria. A major problem that occurs, however, is distinguishing between plasmids that contain 
inserted foreign DNA and vector molecules that have recircularized without insertion of foreign 
DNA. Recircularization of the vector can be limited to some extent by adjusting the 
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concentrations of the foreign DNA and vector DNA in the ligation reaction (Sambrook et al., 
1989). 
 
The easiest fragments to clone carry noncomplementary protruding termini generated by 
digestion with two different restriction enzymes (NdeI and BamHI in this case). The fragment of 
foreign DNA is then inserted into the vector by directional cloning. When preparing vectors for 
directional cloning, restriction sites that are directly adjacent to one another should be avoided, as 
that will not allow for efficient cleavage by many restriction enzymes. After one of these sites has 
been cleaved, the second site will be located within a few base pairs of one end of the linear DNA 
molecule, not being optimal for digestion by the second restriction enzyme.  
 
To make sure that both restriction enzymes have digested the vector to completion, a double 
restriction enzyme digest is sometimes achieved by digesting the DNA one enzyme at a time. 
When the two enzymes prefer buffers of different ionic strengths for optimal catalytical activity, 
the enzyme preferring a lower concentration of salt should be used first. After the first digestion, 
a sample will be checked by gel electrophoresis (to check if all the plasmid DNA has been 
converted from circular to linear molecules), after which the salt concentration will be adjusted 
for digestion by the second enzyme. A control reaction of original circular plasmid should be run 
along with the second digestion, containing only the enzyme used during the second round of 
digestion. After digestion, when checked again with gel electrophoresis, it can therefore be 
determined if digestion was complete. If so, plasmid DNA can be purified using either gel 
electrophoresis or size-exclusion gel chromatography (Sambrook et al., 1989).  
 
To further prevent recircularization (and self-ligation) the 5’-phosphate groups of the DNA 
fragments can be removed using alkaline phosphatase. During ligation in vitro, bacteriophage T4 
DNA ligase will catalyze the formation of a phosphodiester bond between adjacent nucleotides 
only if one nucleotide contains a 5’-phosphate group and the other contains a 3’-hydroxyl group. 
Therefore, by removing the 5’-phosphates from both termini of the linear DNA, recircularization 
of plasmid DNA can be minimized (Sambrook et al., 1989). 
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The ligation mixture used consisted of  2 µl pET28b(+) vector (~ 200 ng DNA), 1 µl 10x ligase 
buffer, 1 U T4 DNA ligase, 2 µl PCR product (~ 1:1 molar ratio to vector DNA) and 4.7 µl 
ddH2O to make up the reaction volume of 10 µl. The mixture was incubated at room temperature 
for 4 hours, after which it was incubated at 15ºC for 18 hours. The ligation product was analyzed 
with agarose gel electrophoresis (section 3.2.1.2). The plasmids obtained in this way were 
transformed into E. coli expression strains as described in sections 3.2.2.1 and 3.2.2.2, followed 
by sequencing to ensure that the protease gene was present and correctly inserted into the 
pET28b(+) expression vector.  
 
 
 
Figure 3.4:  The p28bHIV1PR expression vector. HIV-1 PR cDNA was inserted between the NdeI and BamHI 
sites of the pET28b(+) vector which leads to expressed protein with an N-terminal His-tag, removable 
by thrombin. 
 
3.2.1.6 
 
DNA concentration and purity determination 
UV spectrophotometry was used to determine the concentration and purity of the DNA obtained 
at every stage. An appropriate dilution of the DNA sample was made (usually a 20x dilution by 
p28bHIV1PR 
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kan sequence 
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T7 promoter 
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adding 5 µl DNA sample to 95 µl ddH2O in a 100 µl microcuvette). Absorbance readings were 
measured at wavelengths of 260 and 280 nm.  
 
The purity of the DNA was determined using the OD260nm:OD280nm ratio, where a ratio of 2.00 
indicates 100% nucleic acids and no protein and ratios less than 2.00 indicate an increasing 
amount of protein. Since an OD260nm of 1 equals 50 µg/ml double-stranded or 30 µg/ml single-
stranded DNA or RNA, the DNA concentration was determined by the following two equations 
(Sambrook et al., 1989): 
 
For double-stranded DNA: [DNA] (µg/ml) = OD260nm x 50 x dilution factor.   
For single-stranded DNA: [DNA/RNA] (µg/ml) = OD260nm x 30 x dilution factor. 
 
3.2.2 
 
Expression and purification of HIV-1 protease 
The HIV-1 protease was expressed and purified according to Ido et al. (1991). E. coli strains 
BL21(DE3)pLysS and ROSETTA(DE3)pLysS were used as the host cells to express 
recombinant HIV-1 protease. 
 
3.2.2.1 
 
Competent cells 
Electro-competent cells for the expression of the protease were prepared from stocks obtained 
from Novagen (USA). The E. coli strains BL21(DE3)pLysS and ROSETTA(DE3)pLysS were 
both used for the expression of the HIV-1 protease in order to compare protein yields within each 
strain. 
 
Frozen stocks of both strains were plated onto LB/Cam plates (both strains are chloramphenicol 
resistant), and grown overnight at 37ºC. SOB medium (50ml) containing 36 µg/ml 
chloramphenicol was inoculated with single colonies and grown overnight at 37ºC (with shaking 
at ~ 180 rpm). Overnight cultures were used to inoculate 4 x 1 liter broths of SOB-CAM with 5 
ml of the overnight culture. These cultures were grown to mid-log phase at 37ºC (with shaking at 
~ 180 rpm) to an OD600nm ~ 0.8. Cells were chilled on ice, and the cultures were decanted into 
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chilled sterile centrifuge bottles (which were washed with 30% H2O2, and rinsed with wash 
buffer). The cultures were centrifuged at 3000 x g for 15 minutes at 4ºC. The cells were loosened 
and washed with ice-cold wash buffer [10% (v/v) ultra-pure glycerol, 90% (v/v) ddH2O; 
sterilized by autoclaving and stored at 4ºC]. Cultures were centrifuged at 3000 x g for 25 minutes 
at 4ºC, and the cells were washed as above. Cells were loosened and resuspended (on ice) in ~ 4 
ml wash buffer. Cells were aliquoted into sterile Eppendorf cups (90 µl), snap-frozen in liquid 
nitrogen and stored at -80ºC. 
 
3.2.2.2 
 
Transformation 
E. coli BL21(DE3)pLysS and ROSETTA(DE3)pLysS cells were both transformed with the 
ligated plasmid p28bHIVPR using electroporation. The electrocompetent cells (prepared as 
described in section 3.2.2.1) were thawed on ice, and kept chilled at all times. Plasmid DNA (1 µl 
p28bHIVPR) was pipetted into a pre-chilled microcentrifuge tube, and 40 µl of the chilled 
electrocompetent cells was added. The mixture was transferred to a pre-chilled electroporation 
cuvette. The cuvette was thoroughly dried before electroporation. The cuvette was placed in an 
electroporator and electroporation was carried out at ~ 13000 V/cm with a pulse time of ~ 4 
milliseconds. LB media (960 µl) was immediately added to recover the cells, and the mixture was 
incubated at 37ºC for one hour. Cells (100 µl) were used to make a spread plate (on 
LB/Kan/CAM plates), which was incubated at 37ºC overnight. Single colonies obtained were 
checked by plasmid isolations and restriction digests (section 3.2.1.2) for being the correctly 
transformed p28bHIV1PR recombinant vector. Plasmids were isolated using the Wizard Plus 
Midipreps DNA Purification System (Promega, USA). 
 
3.2.2.3 
 
Expression of HIV-1 protease 
The E. coli cells harbouring plasmid p28bHIV1PR were grown at 37ºC in ZB medium [10 g of 
N-Z-amine (casein hydrolysate) and 5 g of NaCl per liter] with 30 µg/ml kanamycin and 25 
µg/ml chloramphenicol. The overnight culture was diluted 100-fold in Luria broth containing 30 
µg/ml kanamycin and 25 µg/ml chloramphenicol and grown for approximately 3 hours at 37ºC. 
When optical density at 600nm of the culture reached 0.4-0.5, IPTG was added to a final 
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concentration of 0.4 mM. The cultures were grown for another 3 hours, cells harvested by 
centrifugation at 5 000 x g, 30 minutes, 4ºC and stored at -20ºC. 
 
3.2.2.4 
 
Purification of HIV-1 protease 
3.2.2.4.1 
 
Inclusion body isolation 
Cell paste (5 g) was thawed and suspended in 100 ml ice-cold buffer A (10 mM Tris-HCl, pH 
8.0, 2 mM EDTA, 1 mM phenylmethyllsulfonyl fluoride). After standing for 30 minutes at room 
temperature, IGEPAL CA-360 was added to 0.1% (v/v) and stirred gently for 10 minutes at 4ºC. 
MgCl2 and DNase I were added to a final concentration of 10 mM and 4 Kunitz units/ml, 
respectively. When the viscosity of the mixture decreased, the cells were ruptured using 
sonication (5 bursts of 90 seconds each). The cell homogenate was centrifuged at 10 000 x g for 
10 minutes at 4ºC. The pellet was resuspended in ice-cold buffer A as before, containing 1% 
(v/v) Triton X-100, and centrifuged at 10 000 x g for 10 minutes. The pellet, which contained the 
majority of the proteins expressed (as inclusion bodies), was then solubilised in 200 ml buffer B 
(10 mM Tris-HCl, pH7.5, 8 M urea and 10 mM DTT), and centrifuged at 75 600 x g for 30 
minutes at 4ºC.  
 
3.2.2.4.2 
 
Preparative affinity chromatography 
The clear supernatant (200 ml), obtained as described in section 3.2.2.4.1, was transferred onto a 
nickel-affinity column (1 x 5 ml HiTrap Chelating HP, Amersham Biosciences), and subsequent 
separation was achieved in an ÄKTATM chromatography system (Amersham Pharmacia Biotech, 
Sweden). 
 
HiTrap Chelating HP 5 ml columns are packed with 5 ml of Chelating SepharoseTM High 
Performance, consisting of highly cross-linked agarose beads to which iminodiacetic acid has 
been coupled by stable ether groups via a spacer arm (seven atoms). This coupling technique 
gives both high capacity and high performance. The gel is stable over the pH range 3-13, and 
tolerates all commonly used aqueous buffers and denaturants, such as 6 M guanidine 
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hydrochloride, 8 M urea and chaotropic salts. When charged with Ni2+ ions, HiTrap Chelating HP 
selectively retains proteins with complex-forming histidine exposed on their surfaces. Histidine-
tagged proteins can then be eluted from HiTrap Chelating HP with buffers containing imidazole. 
If recombinant His-tagged proteins are expressed as inclusion bodies, 6 M guanidine 
hydrochloride or 8 M urea (as was the case with this study) should be added to all buffers 
(Colangeli et al., 1998). 
 
The column was prepared as follows: The syringe and pump tubing were filled with distilled 
water. The stopper (at the top of the column) was removed and the column was connected to the 
pump tubing, “drop to drop”, to avoid introducing air into the system. The snap-off end (at the 
column outlet) was removed and the column was washed with 15 ml distilled water. Ni2+ was 
loaded onto the column by running 2.5 ml 0.1 M NiSO4 solution through the column. The 
column was washed with 15 ml distilled water, and equilibrated with running buffer (buffer B 
containing 20 mM imidazole). After loading, the unbound protein was washed from the column, 
and the protein was eluted using a linear gradient of 20 mM to 1 M imidazole (over 20 minutes at 
a flow rate of 2 ml/min). Fractions containing protease were then pooled and stored at 4ºC. 
 
After every five purifications on the ÄKTA system, the column was re-generated, ensuring 
optimal results. The column was stripped with 5 column volumes of start buffer containing 0.05 
M EDTA, followed by washing with 5-10 column volumes of distilled water. The column was 
then re-charged with Ni2+ as described above. 
 
3.2.2.4.3 
 
Refolding of HIV-1 protease 
The denatured protease solution in 8 M urea obtained from nickel affinity chromatography was 
acidified by mixing with 0.02 volume of 10% (v/v) trifluoroacetic acid to obtain a final pH of 3.5, 
and refolded by dialysis against 1 mM DTT, 10 mM sodium acetate buffer, pH 3.5 (section 
3.3.3.2). 
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The dialysis time needed for acquiring activity of the protease was determined with an 
experiment where samples were taken at various intervals during the dialysis method, and tested 
for activity using the fluorogenic activity assay (section 3.2.3). 
 
3.2.2.4.4 
 
Gel filtration chromatography 
The clear solution of refolded protein (2 ml injections) was applied to a gel filtration column (Hi 
LoadTM 26/60 SuperdexTM 75 pg column, Amersham Biosciences and later SuperdexTM 200 HR 
10/30 column, Supelco, USA), and eluted with 1 mM DTT, 10 mM sodium acetate buffer, pH 3.5 
at a flow rate of 2 ml/min. The purity of the protein was examined by SDS-polyacrylamide gel 
electrophoresis using a 15% acrylamide resolving gel (Laemmli, 1970). The peak fractions were 
collected, and after the addition of glycerol to a concentration of 10% (v/v), stored at -80ºC. 
 
3.2.2.5 Protein concentration determination
 
  
3.2.2.5.1 
 
Bicinchoninic acid protein assay 
The bicinchoninic acid (BCA) protein assay was used to determine the protein concentration 
obtained at every stage (whenever reducing agents were not present). This assay is based on the 
reduction of Cu2+ to Cu+ by protein in an alkaline medium and the detection of the resulting 
cuprous cation by bicinchoninic acid (Smith et al., 1985). 
 
The working reagent for this assay was prepared by adding 10 ml of reagent A (1 g bicinchoninic 
acid disodium salt, 2 g Na2CO3, 0.16 g sodium tartrate, 0.4 g NaOH and 0.95 g NaHCO3 per 100 
ml at pH 11.25) to 200 µl of reagent B (0.4 g CuSO4.5H2O in 10 ml ddH2O). A standard curve 
for the assay was established by pipetting 20 µl of a bovine serum albumin (BSA) solution (0-3 
mg/ml) and 200 µl of working reagent into a microtitre well plate. The plate was mixed by 
shaking on a Multiscan MS microtitre plate reader, covered and incubated for 30 minutes at 37ºC. 
The absorbance of the plate was measured at 540 nm using a Multiscan MS microtitre plate 
reader (ThermoLabsystems). 
 
52 
 
3.2.2.5.2 
 
Bradford protein assay 
The Bradford protein assay was used to determine the protein concentration whenever reducing 
agents, DTT in this case, were present. This assay is based on the formation of a complex 
between the dye, Brilliant Blue G, and the proteins in solution. The protein-dye complex causes a 
shift in the absorption maximum of the dye from 465 to 595 nm. The amount of absorption is 
proportional to the protein present. The Bradford reagent is compatible with reducing agents, 
which are often used to stabilize proteins in solution, and which other protein assay procedures 
(Lowry and BCA) are not compatible with (Bradford, 1976).  
 
The assay was performed in a 96-well microtitre plate and a standard curve was established 
ranging in BSA concentrations from 0.1-1.4 mg/ml. A volume of 250 µl undiluted Bradford 
reagent was added to each well (containing either 5 µl of BSA solution or 5 µl of protein 
solution). The samples were mixed by shaking on a Multiscan MS microtitre plate reader, 
covered and incubated for 10 minutes at room temperature. The absorbance of the plate was 
measured at 595 nm using a Multiscan MS microtitre plate reader. 
 
3.2.2.6 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
The purity of the protein was examined by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis under reducing conditions (15% acrylamide resolving gel) according to the 
method of Laemmli, (1970). 
 
Electrophoresis is an analytical tool with which to examine the movement of charged molecules 
in an electric field. In the case of SDS-PAGE protein samples are treated with the detergent 
sodium dodecyl sulfate so that they have a uniform charge to mass ratio, and electrophoretic 
mobility depends only on size.  
 
 
 
53 
 
3.2.2.7    
 
Western blotting 
When the SDS-PAGE gels did not give conclusive evidence as to the presence of HIV-1 
protease, a Western blot was performed using the method of semi-dry blotting (Towbin et al., 
1979). Western blotting relies on the principle of transferring proteins to a membrane and 
detecting proteins that react with specific antibodies. Polyvinyl-difluoride (PVDF) membranes 
were used, which bound proteins strongly and, because of their hydrophobic nature, gave light 
background colour after analysis. A sandwich of filter paper, gel, membrane, and more filter 
paper was prepared in a cassette, which was placed between platinum electrodes. An electric 
current was passed through the cassette (25V, 5 mA/cm2 for 45 minutes), causing the proteins to 
electrophorese out of the gel and onto the membrane. The transfer buffer used contained 48 mM 
Tris, 39 mM glycine and 20 % (v/v) methanol at pH 9.2 (Bjerrum and Schafer-Nielsen, 1986). 
 
Detection of recombinant HIV-1 protease was performed with a His•Tag Monoclonal Antibody 
[a mouse monoclonal antibody (IgG) at concentrations between 0.1 and 0.2 µg/ml] that is 
directed against the His•Tag sequence encoded by pET28b(+). Detection is then achieved by 
using a goat anti-mouse IgG alkaline phosphatase conjugate (diluted 1:5000 in blocking solution) 
that develops a solution containing 1.2 mg NBT (nitroblue tetrazolium at a concentration of 83 
mg/ml) and 0.01 mg BCIP (5-bromo-4-chloro-3-indolyl-phosphate at a concentration of 42 
mg/ml). The His•Tag® AP Western Reagents kit (Novagen) supplied all the reagents used during 
the Western, including the method used (Novagen, 2005). 
 
3.2.3 
 
HIV-1 protease fluorogenic assay 
A fluorogenic assay was used for kinetic analysis of purified HIV-1 protease using an HIV-1 
protease fluorogenic substrate, DABCYL-γ-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS 
[HIV-FRET(1)], obtained from Anaspec (USA) as described in Lam et al. (2000). This assay is 
based on intramolecular fluorescence resonance energy transfer (FRET), and uses a quenched 
fluorogenic substrate, containing an octapeptide, with a fluorescent donor (EDANS) and a 
quenching acceptor (DABCYL) attached to the COOH- and NH2-termini, respectively. The 
octapeptide sequence of the substrate corresponds to the naturally occurring Pr55gag p17/p24 
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cleavage site for HIV-1 PR, which cleaves at the Tyr-Pro peptide bond. A γ-aminobutyric acid 
spacer was inserted between the DABCYL group and the NH2-terminal Ser to avoid potential 
steric hindrance of substrate binding by the bulky acceptor (Matayoshi et al., 1990). 
 
Due to intramolecular resonance energy transfer to the DABCYL group, the intrinsic 
fluorescence of EDANS is dramatically reduced in the substrate (Stryer, 1978). Since resonance 
energy transfer becomes insignificant beyond distances of about 100 Å, the full fluorescence 
quantum yield of EDANS is restored after cleavage of the peptide and simultaneous release of the 
DABCYL-linked peptide fragment. Proteolytic activity can therefore continuously be monitored 
by recording the increase in fluorescence intensity with time (Matayoshi et al., 1990). 
 
The substrate was dissolved in DMSO to make a 1 mM stock. The stock fluorogenic substrate 
was diluted to 100 µM with the assay buffer (0.1 M sodium acetate, 1 M NaCl, 1 mM EDTA,     
1 mM DTT and 1 mg/ml BSA, pH 4.7). An aliquot (10 µl) of substrate and 26 µl HIV-1 protease 
solution at 0.95 µg/µl were added to the reaction mixture in an assay buffer to make a final 
reaction volume of 100 µl. The mixture was incubated in the dark at 37ºC for 30 minutes. 
Pepstatin A (at a concentration of 0.5 mg/ml) was used as control for inhibition of HIV-1 
protease. After incubation, 10 µl of 5.5% (w/v) trifluoroacetic acid (TFA) was added to stop the 
reaction. The fluorescence intensity was measured in a spectrofluorometer with an excitation 
wavelength of 355 nm and an emission wavelength of 460 nm.   
 
3.3 
 
Results and Discussion 
3.3.1 
 
Cloning the HIV-1 protease gene 
The presence of the HIV-1 protease gene (approximately 330 bp according to Figure 3.2) in the 
donated pProtease vector was confirmed with restriction digests using HindIII and EcoRI. The 
bands in Figure 3.5 illustrate the DNA fragments obtained during this double restriction digest 
after agarose gel electrophoresis. The molecular weight marker in lane 1 was used to determine 
the sizes of these bands, and thus of the DNA fragments. The expected sizes of the fragments 
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were approximately 2600 bp and 330 bp (thus removing the 330 bp fragment from the 2964 bp 
plasmid). 
 
The sizes of the upper bands obtained were approximately 2800 bp, 3100 bp, 3000 bp and 2700 
bp for lanes 3, 4, 6 and 7, respectively. The sizes of the lower bands obtained were approximately 
320 bp, 310 bp, 290 bp and 280 bp for lanes 3, 4, 6 and 7, respectively. All bands proved to be 
close enough to the expected sizes, verifying the presence of the HIV-1 protease gene and this 
gene was amplified by PCR using specifically designed primers (Figure 3.6). 
 
 
 
Figure 3.5:  Gel (1% agarose) showing double restriction digests of pProtease vector. Lanes all represent digests 
with HindIII and EcoRI. Lane 1 shows the Roche 250 bp molecular weight marker. 
 
Two reverse primers were designed to allow for a choice if results would be so different as to 
show a clear increase in amplification if one is used in conjunction with the designed forward 
primer. After the first few amplifications however, it was clear that both reverse primers would 
be suitable, and reverse primer 2 was then randomly chosen for further amplification reactions. 
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According to the molecular weight marker included in lane 1 (Figure 3.6), all the bands obtained 
were approximately 300 bp (sufficiently close to the expected fragment size of 330 bp). These 
fragments were purified from the gel using the QIAquick Gel Extraction Kit, and eluted from the 
silica-gel membrane (section 3.2.1.3) using a Tris buffer. 
 
These isolated fragments, together with pET28b(+), were digested with NdeI and BamHI in 
preparation for the ligation reaction, and thus the production of p28bHIV1PR (Figure 3.4). 
Restriction with different restriction enzymes allows for directional cloning as discussed earlier 
(see 3.2.1.5), ensuring recognition and ligation of the complementary protruding termini. 
 
 
 
Figure 3.6:  Amplification of HIV-1 protease gene from plasmid pProtease. Lanes represent Roche 250 bp 
molecular weight marker (Lane 1); amplification with reverse primer 1 (Lanes 3-8) at annealing 
temperatures 58ºC (Lanes 3+4); 54ºC (Lanes 5+6) and 52ºC (Lanes 7+8); amplification with reverse 
primer 2 (Lanes 10-15) at annealing temperatures 58ºC (Lanes 10+11); 54ºC (Lanes 12+13) and 52ºC 
(Lanes 14+15). 
 
DNA fragments obtained after restriction digestion were observed using agarose gel 
electrophoresis (Figure 3.7). According to the molecular weight marker included in lane 1, band 
sizes were calculated as being approximately 2900 bp and 330 bp for the upper and lower bands 
obtained in lane 3, respectively; bands in lanes 5-8 were all approximately 330 bp and bands in 
lanes 10, 11, 13, 14, 16, 17, 19 and 20 were all approximately 5500 bp. 
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The fragments were purified from the gel using the QIAquick Gel Extraction Kit, and used in a 
ligation reaction, forming the p28bHIV1PR plasmid. Four such ligation reactions were attempted, 
and the resultant plasmids were designated reactions 2.3, 2.4, 3.3 and 3.4, respectively.  
 
 
 
Figure 3.7:  Digestion of PCR fragments and pET28b(+) with NdeI and BamHI. Lanes represent Roche 250 bp 
molecular weight marker (Lane 1); pProtease digested with HindIII and EcoRI (Lane 3); PCR 
fragments: Reverse primer 1 (Lanes 5+6) and reverse primer 2 (Lanes 7+8); pET28b (Lanes 10, 11, 13, 
14, 16, 17, 19 and 20). 
 
E. coli DH5α cells were transformed with the ligated plasmid (p28bHIV1PR) using 
electroporation. Plasmids were isolated using the QIAGEN Mini-Prep isolation kit, and restricted 
with ClaI and XhoI to confirm that the isolated plasmids were p28bHIV1PR (Figure 3.8). ClaI 
and XhoI were chosen for the restriction digestion, as they were expected to give fragments that 
are large enough, and thus easily visible on an agarose gel. These expected fragments were 3900 
bp, 1400 bp and 250 bp. 
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Figure 3.8:  Double restriction digest of isolated plasmid (p28bHIV1PR) with ClaI and XhoI. Lanes represent 
Roche 250 bp molecular weight marker (Lane 1) and restriction digests of isolated plasmids (Lanes 3, 
5, 7 and 9). Expected fragments were approximately 3900, 1400 and 250 bp. 
 
The obtained DNA fragments were analysed on an agarose gel, and with the presence of a 
molecular weight marker in lane 1, the sizes were determined as being approximately 3900 bp 
and 1450 bp for the upper and lower bands, respectively (lanes 3, 5, 7 and 9). The smaller 
expected band of 250 bp was not visible on the gel, and could have been due to insufficient 
digestion for that specific sized band to be visible on the gel. In isolated cases bands obtained 
were larger than the molecular weight markers seen on the specific gel (see Figure 3.7 and Figure 
3.8), and the sizes of these bands were determined by extrapolating them from a standard curve 
set up using the molecular weight bands that were present. This compromised the accuracy of the 
molecular weight determination of these bands, but was not sufficiently substantial to change the 
outcome of the experiment.  
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Another PCR reaction was performed with the isolated plasmids to confirm that HIV-1 protease 
was incorporated into the ligated plasmid. The same primers (although only reverse primer 2) 
referred to in Figure 3.6 were used for amplification of HIV-1 protease (Figure 3.9). According to 
the molecular weight marker in lane 1, all bands obtained had a size of approximately 330 bp, 
thus proving the presence of the HIV-1 protease gene in the ligated p28bHIV1PR plasmids. 
 
 
 
Figure 3.9:  PCR verification of the presence of HIV-1 protease in the ligated plasmid, p28bHIV1PR. Lanes 
represent Roche 250 bp molecular weight marker (Lane 1); PCR fragments (all with reverse primer 2) 
(Lanes 3-6) Reaction 2.3 (Lane 3); Reaction 2.4 (Lane 4); Reaction 3.3 (Lane 5); Reaction 3.4 (Lane 6). 
Arrow indicates amplified HIV-1 protease. 
 
The four ligated plasmids (reactions 2.3, 2.4, 3.3 and 3.4) were sent for sequencing to ensure that 
the protease gene was present and correctly inserted into the pET28b(+) plasmid, and that no base 
errors were incorporated during PCR amplification by the DNA polymerase. An example of the 
alignment results is provided in Figure 3.10, where the sequence alignment of reaction 2.3 is 
shown with regard to HIV-1 protease.  
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A C to T mutation at nucleotide 387 (reaction 2.3) was observed in sequence alignments of all 
four reactions, but had no effect on the amino acid sequence, as both ACC (codon included in the 
HIV-1 protease sequence) and ACT (codon included in reactions 2.3, 2.4, 3.3 and 3.4) code for 
the amino acid threonine (Figure 3.11). It is important to note that the donated pProtease plasmid 
contains this same mutation at nucleotide 387 for codon usage purposes (Figure 3.1). Thus the 
mutation did not originate from PCR errors (a proof reading DNA polymerase was used during 
PCR), but is inherent in the HIV-1 PR gene obtained from the NIH AIDS Research and 
Reference Reagent Program. The plasmid obtained during the ligation was therefore confirmed to 
be p28bHIV1PR, containing the HIV-1 protease gene. 
 
 
HIV1PR            ---------------AAGCTTACCTGCCAT--GCCGCAAATCACTCTGTGGCAGCGTCCA 43 
rxn2.3t7          AGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCCGCAAATCACTCTGTGGCAGCGTCCA 141 
                                   **    * *****  **************************** 
 
HIV1PR            CTGGTTACCATCAAAATCGGTGGTCAACTAAAGGAAGCTCTGCTGGACACTGGTGCTGAT 103 
rxn2.3t7          CTGGTTACCATCAAAATCGGTGGTCAACTAAAGGAAGCTCTGCTGGACACTGGTGCTGAT 201 
                  ************************************************************ 
 
HIV1PR            GACACCGTTCTCGAGGAAATGTCTTTGCCAGGTCGTTGGAAACCGAAGATGATTGGTGGC 163 
rxn2.3t7          GACACCGTTCTCGAGGAAATGTCTTTGCCAGGTCGTTGGAAACCGAAGATGATTGGTGGC 261 
                  ************************************************************ 
 
HIV1PR            ATTGGTGGTTTCATCAAAGTTCGTCAGTATGATCAAATCTTGATTGAAATCTGTGGTCAC 223 
rxn2.3t7          ATTGGTGGTTTCATCAAAGTTCGTCAGTATGATCAAATCTTGATTGAAATCTGTGGTCAC 321 
                  ************************************************************ 
 
HIV1PR            AAGGCTATTGGTACCGTACTAGTTGGTCCAACTCCTGTAAACATCATTGGTCGTAACCTG 283 
rxn2.3t7          AAGGCTATTGGTACCGTACTAGTTGGTCCAACTCCTGTAAACATCATTGGTCGTAACCTG 381 
                  ************************************************************ 
 
HIV1PR            TTAACCCAGATCGGGTGCACTTTAAACTTCTAGTAAGGATCCGAATTC------------ 331 
rxn2.3t7          TTAACTCAGATCGGGTGCACTTTAAACTTCTAGTAAGGATCCGAATTCGAGCTCCGTCGA 441 
                                           ***** ******************************************             
 
Figure 3.10: DNA sequence alignment of Reaction 2.3 plasmid p28bHIV1PR with HIV-1 PR gene. 
 
3.3.2 
 
Expression of HIV-1 protease 
Protease was first expressed and purified from E. coli BL21(DE3)pLysS cells, but due to very 
low yields, and inconclusive evidence as to the presence of protease on SDS-PAGE gels (Figure 
3.12A), the expressing strain was changed to E. coli ROSETTA(DE3)pLysS cells. 
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Figure 3.11:  The “universal” genetic code. Codon shading varies with the position of the encoded amino acids 
along a hydrophilic-hydrophobic axis: lighter shading indicates more hydrophobic. Termination 
codons are black with a diagonal pattern. Arrows indicate the codons included in either the HIV-1 
PR sequence or reactions 2.3, 2.4, 3.3 or 3.4 sequences [Wu et al., 2005]. 
 
By observation of the SDS-PAGE gel only, the presence of the protease (which is an 11 kDa 
protein) was not apparent, and thus, as the gel analysis did not prove conclusively that protease 
was expressed, a Western blot was performed (Figure 3.12B), using the His•Tag Monoclonal 
Antibody [a mouse monoclonal antibody (IgG)] directed against the His•Tag sequence encoded 
by pET28b(+).  
 
The presence of a definite band obtained through binding of the His•Tag Monoclonal Antibody to 
the His•Tag sequence encoded by pET28b(+), proved that although protease’s presence wasn’t 
very clear on the SDS-PAGE gel, it was indeed expressed and present. It was still worth looking 
at a different E.coli strain for expression though, so that higher levels of expression could be 
attained. 
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A  B  
 
Figure 3.12:  (A) Reducing SDS-PAGE (15% acrylamide gel) of expressed protease in E. coli BL21(DE3)pLysS 
cells. Lanes represent Sigma low molecular weight marker (Lane 1); Fermentas Life Sciences 
Prestained protein ladder (Lane 3), aliquots before induction (Lanes 5+6); aliquots 3 hours after 
induction (Lanes 7+8) and isolated inclusion bodies (Lanes 9+10). (B) Western blot of expressed 
protease. Lane 1 represents Trial mix western markers while the rest of the samples are as 
described in (A). The arrow shows the presence of HIV-1 PR. 
 
For this purpose E. coli ROSETTA(DE3)pLysS cells were used. To find an optimum incubation 
time (and temperature) after induction, aliquots were taken every hour, and cultures were 
incubated at different temperatures (Figure 3.13). Samples were also induced with different 
concentrations of IPTG, to find the optimum concentration that should be added. 
 
Expression being so much clearer from just looking at the SDS-PAGE gels, it was decided to 
change the expressing strain of E.coli from BL21(DE3)pLysS to ROSETTA(DE3)pLysS cells. It 
was also decided to incubate at 37ºC for 3 hours after induction, and to induce with IPTG to a 
final concentration of 0.4 mM, as these parameters showed the best expression of HIV-1 protease 
in terms of incubation temperatures, incubation times and IPTG concentrations (see lane 7 in 
Figure 3.13B).   
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A       B  
 
 
C  
 
Figure 3.13:  Reducing SDS-PAGE (15% acrylamide gels) of expressed proteins in ROSETTA(DE3)pLysS 
cells for different time periods and at different temperatures. Lanes represent Fermentas Life 
Sciences Prestained protein ladder (Lane 1); aliquots before induction (Lanes 3-6 in A); aliquots 1 
hour after induction (Lanes 7-10 in A); aliquots 2 hours after induction (Lanes 3-6 in B); aliquots 3 
hours after induction (Lanes 7-10 in B) and aliquots 4 hours after induction (Lanes 3-6 in C). 
Lanes 3, 4, 7 and 8 were incubated at 37ºC and Lanes 5, 6, 9 and 10 were incubated at 27ºC. Lanes 
7 and 9 were induced with IPTG to a final concentration of 0.4 mM, while Lanes 8 and 10 were 
induced with IPTG to a final concentration of 0.6 mM. The arrows shows the HIV-1 PR expressed.  
 
3.3.3 
 
Purification of HIV-1 protease 
The method of Ido et al. (1991) was used as the basis for purification of HIV-1 protease. This 
method involves isolation of inclusion bodies, followed by Ni2+-chelation affinity 
37°C           27°C          37°C            27°C         37°C           27°C            37°C              27°C 
     37°C             27°C 
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chromatography under denaturing conditions, refolding of the protease by dialysis and finally gel 
filtration chromatography to remove misfolded aggregates of the protease. 
 
3.3.3.1 
 
Trial purifications 
The protease behaved as expected on the HiTrap chelation columns during purification of the 
expressed protein, and a typical chromatogram for the elution of the HIV-1 protease from this 
column is depicted in Figure 3.14. Elution was accomplished between imidazole concentrations 
of approximately 600 mM and 800 mM (between 60 and 80 % of the concentration gradient). 
 
 
 
Figure 3.14:  Chromatogram representative of the elution of HIV-1 protease from the HiTrap Chelating HP 
column (1 x 5ml column) [PRHisTrap04]. Approximately 50 ml of sample was loaded onto the 
column (at a protein concentration of 0.864 mg/ml) and 5 ml fractions were collected. The blue 
line represents the absorbance at 280nm, while the faint grey line represents the conductivity 
reading.  
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Peak tubes were checked on a 15% SDS-PAGE gel (Figures 3.15 and 3.16A). When the protein 
was identified in all the lanes representing the peak tubes, either by observing the SDS-PAGE gel 
(Figures 3.15 and 3.16A) or by doing a Western blot (Figure 3.16B), they were pooled and 
prepared for refolding of the protease.  
 
The chromatogram obtained in Figure 3.14 showed an increase in the absorbance of tubes 20 and 
21 when the imidazole concentration was increased from 20 mM to 1 M. These two tubes, as 
well as tubes 3, 7, 11, 12 and 13 (as control flow-through peaks that would also contain trace 
amounts of the protein) were analysed on a SDS-PAGE gel under reducing conditions (Figure 
3.15). 
 
 
 
Figure 3.15:  Reducing SDS-PAGE (15% acrylamide gel) representative of the peaks obtained from the HiTrap 
HP column (PRHisTrap04; Figure 3.14); peqGOLD Protein Marker II (Lane 1); Flow-through 
peak (Lanes 3-7): Tube 3 (Lane 3); Tube 7 (Lane 4); Tube 11 (Lane 5); Tube 12 (Lane 6); Tube 13 
(Lane 7); Eluted protein peak (Lanes 9-10): Tube 20 (Lane 9) and Tube 21 (Lane 10). The tube 
numbers refer to the fractions indicated in Fig. 3.14. 
 
HIV-1 protease at 11 kDa was clearly represented in tubes 20 and 21, as expected, and these two 
tubes were pooled for further analysis and purification. Protein concentration determination using 
the bicinchoninic acid protein assay determined the protein concentration of this pooled sample to 
be 2.116 mg/ml. 
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Protease seemed to also be present in flow-through peak tubes (see lanes 3-5 in Figure 3.15), 
which could have been due to conditions not being optimal for the initial binding of the protease 
to the nickel-affinity column, including too fast a flow rate, or alternatively over-loading the 
column and exceeding the binding capacity. Modifications to chromatography runs were 
attempted, but the presence of protease in flow-through peaks persisted. Modifications included 
changes in the flow rate of especially the initial binding phase of chromatography to allow 
maximal opportunity for the protease to bind to the column. The yield of protease was therefore 
lowered throughout the purification procedures using the HiTrap HP columns. 
 
A  B  
 
Figure 3.16:  (A) Reducing SDS-PAGE (15% acrylamide gel) of the peaks obtained from the HiTrap HP column 
(PRHisTrap02); Sigma low molecular weight marker (Lane 1); Flow-through peak (Lanes 3-6): 
Tube 4 (Lane 3); Tube 7 (Lane 4); Tube 15 (Lane 5); Tube 20 (Lane 6); Eluted protein peak (Lanes 
7-10): Tube 25 (Lane 7); Tube 26 (Lane 8); Tube 27 (Lane 9) and Tube 29 (Lane 10). (B) Western 
blot of gel observed in (A). Lane 1 represents Fermentas Life Sciences Prestained protein ladder, 
while the rest is as explained in (A). The arrow shows the presence of HIV-1 PR. 
 
To further confirm the presence of HIV-1 protease a Western blot was performed at intervals, and 
when there was doubt about the presence thereof. An example was with the purification run of 
PRHisTrap02 (chromatogram not shown) when a Western blot was deemed necessary to 
establish the definite presence of the protein. The protein did seem to be present when observing 
the SDS-PAGE gel (Figure 3.16A) containing the peak tubes (as well as control flow-through 
peak tubes), but it was not as clearly observable as in other purification runs (for example the run 
shown in Figure 3.14). A Western blot (Figure 3.16B) did prove however, that the protein was 
indeed present, and tubes 25, 26, 27 and 29 were also pooled for further analysis and purification.  
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Bands obtained in lanes 4 and 5 in Figure 3.16 seemed to be correctly sized but then did not 
prove to be protease in the Western blot. This was believed to be due to a fault in the transfer 
from the gel to the membrane rather than protease not being present. A faint band starting to 
develop in lane 4 (Figure 3.16B) also supported this possibility. 
 
The first problems were encountered when the partially purified protease had to be refolded 
before the gel filtration stage of the purification. Precipitation of the protein caused the 
concentration to greatly decrease. Whenever dialyzing against the refolding buffer described by 
Ido et al. (1991), the protein precipitated to such an extent that almost all protein was lost to the 
pellet formed. This was evident when protein concentration determinations were done on the 
resultant supernatant and pellet (which resulted from centrifugation to obtain a workable amount 
of supernatant containing the protein). The supernatant contained only approximately 10 mg of 
the original 25 mg, while the pellet contained the rest (Figure 3.17). It became clear that another 
route would have to be found to refold the protease. 
  
 
 
Figure 3.17:  Reducing SDS-PAGE (15% acrylamide gel) of refolded HIV-1 protease. Lanes represent Sigma 
low molecular weight marker (Lane 1); Pellet after centrifugation to remove precipitate (Lane 3); 
Supernatant after centrifugation to remove precipitate (Lane 5). 
 
The iFOLD Protein Refolding System 1 (Novagen, USA) was then obtained to simplify finding 
an appropriate buffer for refolding the partially purified protease. The iFOLD Protein Refolding 
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System 1 is a systematic screen of refolding conditions for target proteins expressed as bacterial 
inclusion bodies. After cell lysis, membrane components and contaminating proteins within the 
inclusion body pellet are removed by a series of detergent and buffer washes. Purified inclusion 
bodies are reduced and denatured by addition of the reducing agent tris(2-
carboxyethyl)phosphine (TCEP) and detergent N-lauroylsarcosine. The denatured target protein 
is refolded by rapid dilution into the iFOLD 96-well buffer matrix (Figure 3.18; Table 3.1). 
 
 
 
Figure 3.18:  iFOLD Protein Refolding System 1 plate layout. All wells of plate contain 450 µl refolding buffer, 
with the exception of wells F12 and H12, which are reserved for user supplied controls. The final 
concentrations of the constituents in the wells are provided in Table 3.1. Components of the 
iFOLD Protein Refolding System 1 were selected from an extensive literature review, including 
the REFOLD database (http://refold.med.monash.edu.au) Design-Expert® 6 software and rational 
design was used to combine the components in a matrix with maximal diversity and a total of 92 
trials (+ 4 controls). 
 
To test refolding conditions for HIV-1 protease with the iFold system, lysed cells were dialyzed 
against 1 x iFOLD dialysis buffer. Thereafter, the protein sample was diluted to 1 mg/ml with 1 x 
iFOLD dialysis buffer. The refolding matrix was thawed for 120 minutes at room temperature. 
Protein solution (50 µl at 1 mg/ml) was added to each well and rapidly mixed by pipetting up and 
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down at least 10 times. The refolding matrix was gently shaken overnight at room temperature. 
Refolding reaction (100 µl) was transferred to a clear 96-well plate. Absorbance was recorded at 
340 nm using ddH2O as a blank. 
 
Table 3.1: 
 
Components of the iFOLD Protein Refolding System 1 Buffer Matrix 
Buffer  
(50 mM Tris) 
Ionic  
strength 
Detergent  
trap 
Redox 
agents 
Additive 
pH 7.0, 7.5, 8.0 
or 8.5 
NaCl  
100 mM or 250 
mM 
β-Cyclodextrin 
12.5 mM 
TCEP 
1 mM 
Glycerol 
20% (v/v) 
   GSH/GSSG 
3.8/1.2 mM 
PEG 6000 
0.1% (w/v) 
    L-Arg 
500 mM 
    GuHCl 
500 mM 
    CaCl2/MgCl2 
1 mM each 
    EDTA 
1 mM 
 
The extent of precipitation was estimated by measuring the absorbance of samples at 340 nm. 
Soluble protein does not always correlate with correctly folded, active protein, and therefore 
wells that gave low absorbance readings from the refolding reactions, should have been further 
analyzed to verify that the soluble protein was correctly folded and active. Due to limited 
protease substrate available, however, no assays were performed at this time, and the wells with 
the lowest readings were taken as most likely to be refolded, and were used in a preparative 
experiment to determine if these refolding conditions were indeed a better option than the 
original refolding buffer of Ido et al. (1991). Wells giving the lowest readings, and thus the most 
soluble protein product, were wells G9 and H9 shown in Figure 3.18, with buffers both being in 
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the pH range of 8.5. These two buffers were then used in a preparative refolding experiment, 
where with both buffers the protein precipitated similarly to when the refolding buffer as stated in 
Ido et al. (1991) was used.  
 
It was then decided to dialyze the partially purified protease (after the nickel-affinity column) 
back into buffer B (thus eliminating the imidazole in the buffer), before attempting to refold the 
protease. The two iFold buffers, together with the original refolding buffer, were then again used 
to refold the protein. During the refold step, with both the buffers obtained from the iFOLD 
Protein Refolding System 1, the protein sample once again precipitated, while the original 
refolding buffer refolded the protein successfully, as verified with the HIV-1 protease fluorogenic 
activity assay (results not shown). Thus, for refolding, the partially purified protease was dialyzed 
back into the original buffer B (containing no imidazole), acidified with 0.02 volume of 10% 
(v/v) trifluoroacetic acid, and dialyzed against the recommended 1 mM DTT, 10 mM sodium 
acetate buffer, pH 3.5. 
 
To find the best dialysis time for optimal activity of the protease, an experiment was performed 
where samples were taken, while being dialyzed, at different time intervals and assayed for 
activity (Table 3.2). 
 
Table 3.2: 
                
HIV-1 protease activity (measured in fluorescence units) as a function of   
 
refolding time 
Time 
(hours) 
0 6 18 30 42 54 66 72 
Fluorescence 
(Ex.355nm, 
Em.460nm) 
4.65 14.78 12.74 20.01 14.86 14.16 11.57 12.4 
 
Activity was determined to be at an optimum after 30 hours with a fluorescence of 20 
fluorescence units at excitation wavelength 355 nm, and emission wavelength 460 nm (Table 
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3.2). The decline in activity with prolonged refolding times, might be explained by the 
proteolytic activity of the enzyme itself. 
 
To test the possibility of using the Hi LoadTM 26/60 SuperdexTM 75 pg column (Amersham 
Biosciences) for the final gel filtration purification step, protein was extracted from an original 
culture volume of 2 liters, and approximately 86 mg was loaded onto the HiTrap chelating 
column (data not shown). Pooled samples after chromatography contained approximately 25 mg 
of protein, of which only approximately 10 mg remained after dialysis (for the purpose of 
refolding the protein). The 10 mg that remained was loaded onto the Hi LoadTM 26/60 
SuperdexTM 75 pg column, but the purification run showed no clear sign of eluted protein on the 
chromatogram. This was expected though, as the amount of protein loaded was small, and would 
have been diluted further during chromatography.     
 
For further purification of the protease, the refolded protein thus needed to be concentrated to as 
high a concentration as possible for loading onto a gel filtration column. This would have been 
the final step of purification of the active recombinant protease.  
 
Another problem, however, arose with the concentration of the protease samples. Protein seemed 
to be lost as the process of concentrating it continued. Concentration was first attempted using 
Amicon Ultra Centrifugal Filter Devices (5 000 MWCO in this case), but later using 
polyethylene glycol 20 000 (PEG 20000).  
 
Peak tubes from two HiTrap chelating runs (PRHisTrap03 and PRHisTrap04) (chromatogram not 
shown and Figure 3.14, respectively) were pooled, the concentration of the protein determined, 
and concentrated from approximately 25 ml to approximately 7 ml. Tubes 22, 23 and 24 from 
PRHisTrap03 (elution peak obtained) and tubes 20 and 21 from PRHisTrap04 (lanes 9-10 in 
Figure 3.15) were all pooled. The protein concentration was determined (using Bradford 
Reagent) as being 1.44 mg/ml, thus yielding approximately 36 mg of protein for the combined 
volume of approximately 25 ml). The sample was then concentrated for approximately 210 
minutes over PEG 20000, to a volume of approximately 7 ml. The protein concentration was 
determined as being 2.29 mg/ml (thus approximately 16 mg of protein). This loss of protein was 
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observed whenever it was attempted to concentrate the protease, either with the Centrifugal Filter 
Devices or using PEG 20000. The protease was, however, active (verified with the HIV-1 
protease fluorogenic activity assay) with fluorescence readings of on average 15 fluorescence 
units (when using approximately 25 µg of PR in the assay) after concentration (thus with an 
activity of 92 mM/min per milligram of enzyme). 
  
Injections of 2 ml of concentrated sample were loaded onto the Superdex75 gel filtration column 
(approximately 4.5 mg of protein), but due to further dilution of the sample passing through the 
column, and the low protein concentration prior to injection, only very small elution peaks 
(Figure 3.19) were visible, and checking these peaks with electrophoresis showed no evidence of 
the presence of the protease (gel not shown). 
 
The SuperdexTM 200 HR 10/30 gel filtration column was then considered, due to the analytical 
nature of the column (23.562 ml Vt compared to the 318.557 ml of the Superdex75 column), and 
thus less dilution of the sample during chromatography. Samples were not concentrated, 
however, trying to retain as much protein as possible. This, however, meant that only 
approximately 1.44 mg of protein was loaded onto the column at a time, which proved to be too 
little as no peaks were visible (chromatogram not shown). 
 
Protein purified by four other purifications (PRHisTrap05, PRHisTrap06, PRHisTrap07 and 
PRHisTrap08) were pooled to further discover that after changing the gel filtration column for 
the final purification step to the SuperdexTM 200 HR 10/30 column, the sample could still not be 
seen on a SDS-PAGE gel due to its low concentration. This column was tried to minimize further 
dilution of the sample. Each of these purifications also started with the extraction of protein from 
2 liter cultures. The pooled partially purified protein after metal chelation chromatography (Table 
3.3) from these four purifications was first dialysed back into Buffer B (removing any amount of 
imidazole), and refolded (with the recommended refolding buffer of 1 mM DTT, 10 mM sodium 
acetate buffer, pH 3.5). After the refolding step approximately 30 mg of the protein remained, 
which was then applied to the SuperdexTM 200 HR 10/30 column. With the amount of protein 
already being greater than the amount loaded onto the Hi LoadTM 26/60 SuperdexTM 75 pg 
column previously, and the smaller column size (and thus reduced further possible dilution of the 
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sample), it was suspected as being a definite improvement in terms of column choice. The one 
peak obtained was analysed on a SDS-PAGE gel, but the absorbance of this peak was still 
negligibly small (just over 15 mAU), and a definite band on the SDS-PAGE gel was not visible 
(results not shown). It was therefore concluded that neither the Hi LoadTM 26/60 SuperdexTM 75 
pg nor the SuperdexTM 200 HR 10/30 column could be used for final purification.    
 
 
 
Figure 3.19:  Chromatogram representative of the elution of HIV-1 protease from the Hi LoadTM 26/60 
SuperdexTM 75 pg column. Approximately 2 ml of sample was loaded onto the column (at a 
protein concentration of 2.29 mg/ml) and 2 ml fractions were collected. The blue line represents 
the UV reading obtained, while the faint grey line represents the conductivity reading. 
 
It was decided to use the partially purified protease (refolded after the nickel-affinity column) 
from a preparative purification (Section 3.3.3.2) for kinetic studies (Chapter 5), because it 
appeared that the protease cannot be concentrated sufficiently to inject a sufficient amount of 
protein onto either the Superdex75 or the Superdex200 columns to obtain absolutely pure protein 
at a workable concentration. 
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Table 3.3: 
 
Partial purification of HIV-1 PR using the HiTrap column 
 PRHisTrap05 PRHisTrap06 PRHisTrap07 PRHisTrap08 
Amount of protein loaded 
onto HiTrap chelating 
column 
73 mg 83 mg 72 mg 73 mg 
Amount of protein 
recovered from HiTrap 
chelating column 
14 mg 16 mg 13 mg 11 mg 
 
3.3.3.2 
 
Preparative purification of HIV-1 protease 
The procedure followed to obtain refolded, active protease was thus as follows: Cells expressing 
HIV-1 protease were thawed and lysed, the inclusion bodies (containing the majority of the 
protease) were solubilised, and a supernatant containing the protein was obtained. This 
supernatant was filtered and applied to a nickel-affinity column, where the protease was eluted in 
a defined peak. The purity of the eluted protein was then examined by SDS-PAGE (15% 
acrylamide gel). Tubes containing the HIV-1 protease were pooled, dialyzed free of imidazole, 
acidified with 0.02 volume of 10% (v/v) trifluoroacetic acid, and refolded by dialysis against       
1 mM DTT, 10 mM sodium acetate buffer, pH 3.5 for 30 hours at room temperature (Table 3.2). 
Glycerol was added to a concentration of 10% (v/v), and the protease was stored in aliquots at      
-80ºC. 
 
A complete and successful purification was executed in PRHisTrap09, which also originated 
from 2 liters of culture. Approximately 40 ml of sample (containing approximately 62 mg of 
protein) was loaded onto the HiTrap column, and was eluted while collecting 5 ml fractions. The 
peak eluted into 3 tubes (Figure 3.20), which were analysed on a SDS-PAGE gel (Figure 3.21). 
Protease was observed as being present in all three these tubes (easily observable as in Figure 
3.15) and pooled. The protein concentration was determined (Table 3.4) to be 1.27 mg/ml 
(approximately 20 mg of protein). 
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Figure 3.20:  Chromatogram representative of the elution of HIV-1 protease from the HiTrap Chelating HP 
column (1 x 5ml column) [PRHisTrap09]. Approximately 40 ml of sample was loaded onto the 
column (at a protein concentration of 1.550 mg/ml) and 5 ml fractions were collected. The blue 
line represents the absorbance at 280nm, while the faint grey line represents the conductivity 
reading. 
 
The pooled samples were dialyzed against buffer B in a volume ratio of 1:10, acidified and 
refolded by dialysis into the recommended dialysis buffer (Ido et al., 1991), also in a ratio of 
1:10. Activity was detected and measured as on average 7 fluorescence units, when 
approximately 13 µg was used in the HIV-1 protease fluorogenic assay (thus with a specific 
activity of 83 mM/min per milligram of enzyme).  
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Table 3.4: 
 
Purification of HIV-1 PR after expression in E. coli strain ROSETTA(DE3)pLysS 
Procedure Volume 
(ml) 
Protein 
concentration 
(mg/ml) 
Total 
protein 
(mg) 
Yield$ 
(%) 
Specific enzyme 
activity 
(mM/min/mg) 
Protein expression 2000 - - -  
Inclusion bodies 40 1.55 62 100  
Affinity 
chromatography  
15 1.27 19 31  
Protein refold  15 1.03 15 25 83 
 
$; Yield is based on total protein, since enzyme activity cannot be determined until after refolding, the final step in 
    the purification 
 
 
 
Figure 3.21:  Reducing SDS-PAGE (15% acrylamide gel) of the peaks obtained from the HiTrap HP column 
(PRHisTrap09; Figure 3.20); peqGOLD Protein Marker II (Lane 1); Flow-through peak (Lanes 2-
7): Tube 3 (Lane 2); Tube 5 (Lane 3); Tube 7 (Lane 4); Tube 9 (Lane 5); Tube 10 (Lane 6); Tube 
11 (Lane 7); Eluted protein peak (Lane 8-10): Tube 14 (Lane 8); Tube 15 (Lane 9) and Tube 16 
(Lane 10). 
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3.4 
 
Conclusion 
Being cloned into a pUC18 cloning vector, the HIV-1 protease gene needed to be sub-cloned into 
an appropriate expression vector, which was decided to be pET28b(+). This expression vector 
was used as it codes for a histidine tag necessary for purification of the expressed protein using 
the HiTrap Chelating HP column. The histidine tag could be removed after final purification 
(which was never achieved) using thrombin.  HIV-1 protease was amplified for ligation into 
pET28b(+) with gene specific designed primer pairs. Two reverse primers were initially 
examined. They gave similar results, however, so that it was decided to use only reverse primer 2 
for further experiments.  
 
After successful ligation of the HIV-1 protease gene and pET28b(+), expression was examined in 
two E. coli strains; BL21(DE3)pLysS cells and ROSETTA(DE3)pLysS cells. It seemed that 
expression was more clearly visible by examination of SDS-PAGE gels when expressed in 
ROSETTA(DE3)pLysS cells, although both strains expressed the protein. For reduced effort, in 
terms of not needing to do a Western blot after every expression, as well as higher levels of 
expression, it was decided to use ROSETTA(DE3)pLysS cells for expression of HIV-1 protease. 
pLysS was essential for expression by the host as HIV-1 protease is toxic to the bacterium (as 
mentioned in Ido et al., 1991). 
 
According to Ido et al. (1991) HIV-1 protease appears as a distinct 11 kDa band when analysed 
using SDS-PAGE, while a 14 kDa fusion protein can also be detected as a minor band when 
doing a Western blot. This 14 kDa fusion protein undergoes rapid autoproteolysis in the bacterial 
cells to become the 11 kDa mature protease, which then accumulates as inclusion bodies. In their 
study they included a mutated protease in which residue Ala28 was mutated to serine. This 
resulted in a new hydrogen bond of the hydroxyl group of Ser28 to active-site Asp25, which is 
normally absent. The resultant proteolysis in the native enzyme, which was absent in the mutated 
version, thus indicated autoproteolysis rather than bacterial proteolysis in the maturation process 
of the enzyme. Two bands were present throughout our experiments, which proved to be the 
mature protease and fusion protein at 11 kDa and 14 kDa, respectively, although the ratio seemed 
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to favour the 14 kDa fusion protein (Figure 3.16). Enough active 11 kDa protease was, however, 
present to measure activity and do subsequent kinetic studies after refolding.   
 
Ido et al. (1991) used the E. coli strain BL21(DE3)pLysS for expression of their protease, and 
used the expression vector pET3b for cloning purposes. The pET3b expression vector differs 
from the pET28b(+) expression vector in that pET3b does not contain a histidine tag and is 
ampicillin resistant. Ido et al. (1991) thus used anion exchange chromatography (DEAE column) 
for the first part of protease purification, while in the present study affinity chromatography 
(HiTrap Chelating HP column) was used. It was assumed that affinity chromatography would 
yield a purer protein in higher yields, due to the high capacity and specificity of the column.  
 
Purification of the protease was based on the methods used by Ido et al. (1991), although other 
methods are available. Rittenhouse et al. (1990) described a method using pepstatin-agarose for 
the purification of HIV-1 and HIV-2 proteases expressed in soluble form in different recombinant 
E. coli strains. Great losses of protease occurred, however, during the subsequent low-salt/high-
salt wash cycles. The method described by Ido et al. (1991) was chosen as it ensured relatively 
high levels of expression and rapid purification of HIV-1 protease.  
 
Purification from the HiTrap Chelating HP column produced partially purified protease. Attempts 
to refold the protease using the method of Ido et al. (1991) only resulted in precipitation of the 
protease, which continued when various other combinations within a possible refolding buffer 
were examined (made possible with the iFOLD Protein Refolding System 1). It was determined, 
however, that when the imidazole (still present in the sample after elution from the HiTrap 
Chelating HP column) was removed, the recommended refolding buffer of 1 mM DTT, 10 mM 
sodium acetate (pH 3.5) refolded the protein into its active conformation.  
 
The active refolded partially purified protein could not be purified further due to the inability to 
concentrate the protein sufficiently for loading onto the gel filtration columns available. The 
protein was, however, present and active as HIV-1 protease, as was determined with the HIV-1 
protease specific fluorogenic assay performed for kinetic studies (Chapter 5).  
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Alternative methods for measuring HIV-1 protease activity are available according to the 
literature, for example reverse phase HPLC separation of cleavage products of a synthetic 
substrate (Wan et al., 1996). This assay is based on sequence specific cleavage of a synthetic 
peptide that mimics the retroviral polyprotein cleavage site (p17/p24) of HIV-1 PR. The cleavage 
products are then analyzed using reverse phase HPLC (Lam et al., 2000). The fluorogenic assay 
however, proved simpler and adequate for the purpose for which it was used.   
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Chapter 4 
 
HIV-1 Integrase 
4.1 
 
Introduction 
As mentioned in Chapter 1, HIV-1 integrase is a 32 kDa polypeptide that is necessary for the 
stable integration of the viral genome into host DNA. Integrase catalyzes the 3’ processing of the 
linear viral cDNA and the subsequent cDNA strand transfer reaction that inserts the viral DNA 
ends into host DNA. Although full-length integrase is required for 3’ processing and DNA strand 
transfer activities in vitro, the central core domain of integrase is sufficient to catalyze an 
apparent reversal of the DNA strand transfer reaction, termed disintegration (Chow et al., 1992). 
 
Structural studies of HIV-1 integrase have been impeded by the low solubility of the protein, and 
systematic replacement of hydrophobic residues was attempted to increase the solubility of the 
protein. Site-directed mutagenesis was used to replace the hydrophobic residues within the 
catalytic core domain with either alanine or lysine. A single substitution of lysine for 
phenylalanine at position 185 resulted in a core domain that was highly soluble, and its structure 
was determined by X-ray crystallography (Jenkins et al., 1995; Dyda et al., 1994).  
 
HIV-1 integrase is prepared and expressed in an E. coli strain optimized for integrase expression 
and purified using gel filtration chromatography (Jenkins et al., 1995). HIV-1 integrase has been 
expressed mainly in BL21(DE3) cells (Jenkins et al., 1996).  
 
The activity of HIV-1 integrase was tested using a non-radioactive enzyme linked assay in which 
linearized pBluescript SK was immobilized as target DNA in a 96-well microtitre plate. Viral 
DNA and HIV-1 integrase are then added to this immobilized target DNA, and the integration 
reaction is allowed to occur. During integration, biotinylated viral DNA is integrated into the 
immobilized DNA and the biotin is then detected using streptavidin-conjugated alkaline 
phosphatase. The alkaline phosphatase activity is measured with its substrate p-nitrophenyl 
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phosphate. A coloured product results from p-nitrophenyl phosphate being cleaved, thus an 
increase in yellow-coloured product that can be measured at 405 nm, indicates successful 
integration (Chang et al., 1996).  
 
4.2 
 
Methodology 
4.2.1 
 
Amplifying the HIV-1 integrase expression vector 
The NIH AIDS Research and Reference Reagent Program donated a strain of Escherichia coli 
HB101 transformed with a pET15b expression vector (Figure 4.1) into which a mutated HIV-1 
integrase gene had been cloned to the NMMU Biochemistry and Microbiology laboratory. This 
plasmid, pINSD.His.Sol contains the HIV-1 integrase coding sequence mutated to introduce the 
amino acid substitutions F185K and C280S. These modifications within the catalytic core 
domain result in a more soluble protein than native HIV-1 integrase (Jenkins et al., 1996). 
 
4.2.1.1 
 
Plasmid purification 
Streak plates of the stock, ampicillin-resistant transformed HB101 bacteria, were made on 
LB/Amp plates. Single colonies were inoculated into 50 ml Super Broth (Biofluids), containing 
100 µg/ml ampicillin, and incubated overnight at 37ºC with gentle shaking on an orbital shaking 
platform. Plasmid isolation of pINSD.His.Sol was performed using the QIAGEN Mini-Prep 
isolation kit (section 3.2.1.1 for principle of QIAGEN plasmid purification protocols). 
 
4.2.1.2 
 
Restriction digestion 
The isolated plasmids were tested using restriction digests by NdeI and BamHI. The double 
restriction digest reaction contained 3 U NdeI, 3 U BamHI, 1 µl Buffer B, 5 µl isolated plasmid 
and 3.7 µl ddH2O to make up the reaction volume of 10 µl. This reaction mixture was incubated 
at 37ºC for 1 hour, after which it was analyzed using agarose gel electrophoresis. With agarose 
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gel electrophoresis the number and size of the digested fragments, by way of a sized marker, 
could be determined.    
 
 
 
Figure 4.1: Vector map of pET15b [http://www.merckbiosciences.co.uk
 
 5 January 2009]. 
4.2.1.3 
 
DNA concentration and purity determination 
UV spectrophotometry was used to determine the concentration and purity of the DNA obtained 
as described in section 3.2.1.6. 
 
4.2.2 
 
Expression and purification of F185K/C280S integrase from E. coli 
Plasmid pINSD.His.Sol encoding integrase (IN)1-288/F185K/C280S was expressed in E. coli 
strain BL21(DE3) as described in Sherman and Fyfe (1990). Although BL21(DE3) cells were 
used for expression of HIV-1 integrase, the plasmid tended to be unstable in this host, and backup 
stocks in HB101 were kept at all times.   
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4.2.2.1 
 
Competent cells 
Electro-competent E. coli strain BL21(DE3) cells for the expression of the integrase were 
prepared from stocks obtained from Novagen (USA) as described in section 3.2.2.1. 
 
4.2.2.2 
 
Transformation 
E. coli BL21(DE3) cells were transformed with the isolated plasmid using electroporation as 
described in section 3.2.2.2.  
 
4.2.2.3 
 
Expression of HIV-1 integrase 
The E. coli cells harbouring the isolated pINSD.His.Sol plasmid were grown in 2 litres of Super 
Broth, containing 100 µg of ampicillin per ml, at 37ºC until the optical density of the culture was 
between 0.8 and 1.0 at 600nm. Protein expression was induced by the addition of IPTG to a final 
concentration of 0.4 mM. After 3 hours, the cells were harvested and suspended in 12 ml of 25 
mM HEPES (pH 7.5), frozen in liquid nitrogen and stored at -80ºC. 
 
4.2.2.4 
 
Purification of HIV-1 integrase 
4.2.2.4.1 
 
Preparative affinity chromatography 
Frozen resuspended cells expressing IN1-288/F185K/C280S from 6 litres of Super broth were 
thawed and resuspended in lysis buffer (1M NaCl, 20 mM HEPES, pH 7.5, 2 mM β-
mercaptoethanol, 0.3 mg/ml lysozyme, 5 mM imidazole) to a final volume of  250 ml. After a 30 
minute incubation at 4ºC, the lysed cells were sonicated and centrifuged for 1 hour at 40 000 x g. 
The supernatant was filtered through a 0.25 µm filter and applied to a nickel-affinity column (1 x 
5 ml HiTrap Chelating HP, Amersham Biosciences), and subsequent separation was achieved in 
an ÄKTATM chromatography system (Amersham Pharmacia Biotech, Sweden).  
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The column was prepared as explained in section 3.2.2.4.2, and equilibrated with running buffer 
(2 5  mM HEPES,  p H 7 .5 ,  2  M NaCl, 2  mM β-mercaptoethanol and 20 mM imidazole). The 
protein was eluted with a linear gradient of 20 mM to 1 M imidazole (Jenkins et al., 1996). 
 
4.2.2.4.2 
 
Cation exchange chromatography 
Fractions obtained from chromatography using the HiTrap Chelating HP column, containing 
integrase, were pooled and EDTA was added to a final concentration of 5 mM. The sample was 
dialyzed against 20 mM sodium phosphate buffer, pH 6.2, 0.3 mM NaCl, 1 M urea, 1 mM DTT, 
1 mM EDTA and 10% (w/v) glycerol. The dialysate was loaded onto a Mono STM HR 5/5 
column (Pharmacia, Sweden) and eluted with a linear gradient of 0.25 M to 0.6 M NaCl, 
containing 1 M urea, 1 mM DTT, 1 mM EDTA and 10% (w/v) glycerol. Fractions containing 
full-length protein were pooled, dialyzed against storage buffer (1 M NaCl, 20 mM HEPES, pH 
7.5, 1 mM EDTA, 1 mM DTT and 10% (w/v) glycerol), frozen in liquid nitrogen and stored at    
-80˚C (Jenkins et al., 1996).  
 
4.2.2.5 
 
Protein concentration determination 
Protein concentrations were determined throughout the experiments using the methods explained 
in section 3.2.2.5.1 (whenever reducing agents were absent) and section 3.2.2.5.2 (whenever 
reducing agents were present). 
 
4.2.2.6 
             
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
 
PAGE) 
The purity of the protein was examined throughout using sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis under reducing conditions (15% acrylamide resolving gel) according to the 
method of Laemmli, (1970) as explained in section 3.2.2.6. 
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4.2.2.7 
 
Western blotting 
The presence of HIV-1 integrase was verified at various stages using Western blots and the 
method of semi-dry blotting (Towbin et al., 1979). The method and reagents used were as 
described in section 3.2.2.7. 
 
4.2.3 
 
Integrase activity assay 
A non-radioactive enzyme linked HIV-1 integrase assay was performed to identify HIV-1 
integrase activity, according to the DNA-coated plates method described in Chang et al. (1996), 
with some modifications by Au et al. (2000). 
 
4.2.3.1 
 
Target DNA preparation 
pBluescript SK (1µg) was linearized with SmaI and coated onto each well of a 96-well microtitre 
plate, in the presence of 2 M NaCl. These plates were incubated for 2 hours at 37ºC and washed 
three times with distilled water. Unreacted areas of the plate were blocked with 250 µl of 1% 
(w/v) BSA in phosphate buffered saline for 1 hour, and then stored overnight at 4ºC. 
 
4.2.3.2 
 
Donor DNA preparation 
The donor DNA was prepared by annealing 6 nanomoles VU5BR (5’-biotin-
GTGTGGAAAATCTCTAGCAGT-3’) and 7 nanomoles VU5 (5’-
ACTGCTAGAGATTTTCCACAC-3’) for 1 minute at 80ºC in 10 mM Tris-HCl, pH8.0, 1 mM 
EDTA and 0.1 M NaCl, followed by 30 minutes at room temperature. 
 
The integrase reaction was then performed using 50 µl donor DNA and 10 µg integrase, by 
incubation for 1 hour at room temperature, in 20 mM HEPES pH 7.5, containing 10 mM MnCl2, 
30 mM NaCl, 10 mM dithiothreitol and 0.05% IGEPAL CA-630 (Sigma, USA). 
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After the integration reaction, the biotinylated DNA immobilized on the wells was detected by 
incubation for 1 hour at room temperature, with 100 µl streptavidin-conjugated alkaline 
phosphatase (at 1 µg/ml in blocking buffer), followed by colourimetric detection with 50 µl of 1 
mg/ml p-nitrophenyl phosphate in 10% (v/v) diethanolamine buffer pH 9.8, containing 0.5 mM 
MgCl2. The absorbance due to the alkaline phosphatase reaction was measured at 415 nm (Au et 
al., 2000).   
 
4.3 
 
Results and Discussion 
4.3.1 
 
Amplification and expression of the HIV-1 integrase vector 
The presence of the HIV-1 integrase gene in the isolated plasmid pINSD.His.Sol was confirmed 
by restriction digestion with NdeI and BamHI, after transformation into E. coli BL21(DE3) cells. 
The bands in Figure 4.2 illustrate the DNA fragments obtained by this double restriction digest. 
The molecular weight marker in lane 1 was used to determine the sizes of these bands, and thus 
of the DNA fragments.  The expression vector pET15b has a size of approximately 5700 bp, 
consequently with the integrase gene cloned into the vector, fragments of approximately 5700 bp 
and 900 bp were expected.  
 
The sizes of the upper bands obtained were approximately 4000 bp, 5900 bp, 6000 bp, 5800 bp, 
4100 bp, 6000 bp, 6000 bp and 5400 bp for lanes 4-11, respectively. The sizes of the lower bands 
obtained were approximately 890 bp, 4200 bp and 900 bp for lanes 7, 9 and 11 respectively. Lane 
9 showed two bands, which can be explained by the plasmid not being digested completely, since 
the lower band corresponds with that of undigested plasmid shown in lanes 4 and 8. It also means 
that the gel shows that the plasmid adopted different conformations, and was isolated 
successfully.  
 
As described in Chapter 3, when the larger marker (lane 2 in Figure 4.2) could not be used for 
size-determination (due to the clarity of the marker not being optimal), the sizes of the bands 
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were determined by extrapolating them from a standard curve set up using the molecular weight 
bands that were present (the bands of the smaller marker in this case, lane 1 in Figure 4.2). 
 
   
 
Figure 4.2: Gel (1% agarose) showing restriction digests to verify isolation of pINSD.His.Sol. Lanes represent  
Roche 250 bp molecular weight marker (Lane 1); isolated plasmid (control) (Lanes 4 + 8); isolated 
plasmid digested with NdeI (Lanes 5 + 9); isolated plasmid digested with BamHI (Lanes 6 + 10) and 
isolated plasmid digested with NdeI and BamHI (Lanes 7 + 11). Arrow shows the presence of the lower 
bands.  
 
Transformed E. coli BL21(DE3) cells were grown at 37ºC until the optical density of the culture 
was between 0.8 and 1.0 at 600nm. Expression was induced by addition of IPTG to a final 
concentration of 0.4 mM. After allowing growth for another 3 hours, the cells were harvested by 
centrifugation, resuspended in HEPES buffer, frozen in liquid nitrogen and stored at -80ºC. To 
verify the presence of integrase (HIV-1 integrase is a 32 kDa protein), these cells were lysed and 
examined with SDS-PAGE (Figure 4.3A). 
 
Due to inconclusive evidence, as to the presence of HIV-1 integrase, just by observing the SDS-
PAGE gel, a Western blot (Figure 4.3B) was performed using a His•Tag Monoclonal Antibody 
that is directed against the His•Tag sequence encoded by pET15b. The band visible on the 
Western blot around 33 kDa proved that although integrase’s presence was not very clear on the 
SDS-PAGE gel, that it was indeed expressed and present.  
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A    B  
  
Figure 4.3: (A) Reducing SDS-PAGE (12% acrylamide gel) of expressed integrase in E. coli BL21(DE3) cells.   
Lanes represent Sigma low molecular weight marker (Lane 1); Fermentas Life Sciences Prestained 
protein ladder (Lane 2); sample taken before induction (Lane 4); sample taken 1 hour after induction 
(Lane 5); sample taken 2 hours after induction (Lane 6); sample taken 3 hours after induction (Lane 7) 
and sample stored overnight (3 hours after induction) and lysed the next day for further purification 
(Lane 8). (B) Western blot of gel shown in (A). Lanes are as explained in (A). Arrow shows the 
migration of HIV-1 integrase. 
 
The soluble mutant of integrase referred to in Jenkins et al. (1996) also migrated to just above the 
31 kDa marker. They also mentioned that the mutated integrase migrated slightly slower than the 
wild-type integrase included in their study, as this protein contained a histidine tag.   
 
4.3.2 
 
Purification of HIV-1 integrase 
Several attempts at purification of HIV-1 integrase were performed according to the method of 
Jenkins et al. (1996). Briefly, frozen resuspended cells were thawed, lysed, sonicated and 
centrifuged. The resultant supernatant was filtered and applied to a nickel-affinity column 
(HiTrap Chelating HP 1 x 5 ml) equilibrated with a 25 mM HEPES, pH 7.5, 2 M NaCl, 2 mM β-
mercaptoethanol and 20 mM imidazole buffer. HIV-1 integrase was eluted using a linear gradient 
of 20 mM – 1 M imidazole (Figure 4.4). 
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Figure 4.4: Chromatogram representative of the elution of HIV-1 integrase from the HiTrap Chelating HP column  
(1 x 5ml column) [INHisTrap01]. Approximately 50 ml of sample was loaded onto the column (at a    
protein concentration of 4.67 mg/ml) and 5 ml fractions were collected. The blue line represents the 
absorbance at 280nm, while the faint grey line represents the conductivity reading. 
 
The tubes that showed peak absorbance were examined with SDS-PAGE (Figure 4.5). Tubes 
containing HIV-1 integrase needed to be identified so that dialysis into 20 mM sodium phosphate 
buffer, pH 6.2, 0.3 mM NaCl, 1 M urea, 1 mM DTT, 1 mM EDTA and 10% (w/v) glycerol could 
occur, for loading onto the Mono S column. 
 
Integrase could not be detected on the gel, but the peak tubes eluted with imidazole were 
expected to contain integrase, and were thus pooled and, after addition of EDTA to a final 
concentration of 5 mM, dialyzed against 20 mM sodium phosphate buffer, pH 6.2, 0.3 mM NaCl, 
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1 M urea, 1 mM DTT, 1 mM EDTA and 10% (w/v) glycerol. The dialyzed integrase sample was 
then examined with SDS-PAGE (Figure 4.6). 
 
 
 
Figure 4.5: Reducing SDS-PAGE (15% acrylamide gel) representative of the peaks obtained in INHisTrap01  
(Figure 4.4), Lanes represent Fermentas Life Sciences Prestained protein ladder (Lane 1); Tube 4 (Lane 
3); Tube 7 (Lane 4); Tube 10 (Lane 5); Tube 21 (Lane 6); Tube 22 (Lane 7); Tube 23 (Lane 8). 
 
  
 
Figure 4.6: Reducing SDS-PAGE (15% acrylamide gel) of the pooled integrase samples obtained from peak tubes 
(Figure 4.5) after dialysis. Lanes represent Tube 7 (Lane 2); Sigma low molecular weight markers (Lane 
5) and Dialyzed sample (Lane 8). 
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As observed on the gel, the integrase in the dialyzed sample could still not be detected on the gel, 
while the total protein was at a very low concentration (0.7 mg/ml, determined with a BCA 
protein concentration determination assay). Further chromatography was performed by loading 
the pooled sample (15 ml, thus approximately 10 mg) onto the Mono S column in an attempt to 
concentrate the enzyme, and eluted with a linear gradient of 0.25 M NaCl to 0.6 M NaCl. No 
clear elution occurred however (data not shown), which could have meant that the integrase in 
the sample might have been too dilute to be ‘visible’ on the chromatogram. 
 
Since it became clear that integrase was being expressed at low levels, two more runs on the 
HiTrap chelating HP column were performed (INHisTrap02 and INHisTrap03, chromatograms 
not shown) with freshly lysed E. coli cells. The fractionated peaks were analyzed by SDS-PAGE 
(Figure 4.7A), followed by a Western blot (Figure 4.7B) to confirm the purification of integrase 
by the affinity chromatography step.  
 
A  B  
 
Figure 4.7: (A) Reducing SDS-PAGE (15% acrylamide gel) representative of the peaks obtained in INHisTrap02 
and INHisTrap03, Lanes represent Sigma low molecular weight marker (Lane 1); Flow-through peak 
tubes of run INHisTrap02: Tube 6 (Lane 3) and Tube 10 (Lane 4); Peak tubes of run INHisTrap02: Tube 
17 (Lane 5) and Tube 18 (Lane 6); Flow-through peak tubes of run INHisTrap03: Tube 27 (Lane 7) and 
Tube 31 (Lane 8) and peak tubes of run INHisTrap03: Tube 37 (Lane 9) and Tube 38 (Lane 10). (B) 
Western blot of gel obtained in (A). Lane 1 represents Fermentas Life Sciences Prestained protein 
ladder, while the rest is as explained in (A). Arrow shows the presence of HIV-1 integrase. 
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The Western blot thus proved that integrase is present in the peak tubes eluted from the HiTrap 
Chelating HP column by the imidazole buffer. The eluted peaks were pooled from two successive 
runs on the HiTrap Chelating HP column and dialyzed against 20 mM sodium phosphate, pH 6.2, 
0.3 mM NaCl, 1 M urea, 1 mM DTT, 1 mM EDTA and 10% (w/v) glycerol. Samples were 
concentrated down to 500 µl each (using Amicon Ultra Centrifugal Filter Devices 5,000 MWCO) 
yielding total protein concentrations of 2.08 mg and 2.24 mg, respectively. These samples were 
loaded onto the Mono S column but once again there was no clear elution profile of HIV-1 
integrase (data not shown). 
 
Three more runs on the HiTrap Chelating HP column were completed, with profiles similar to the 
one obtained in Figure 4.4. The peak tubes of all three runs were pooled and dialyzed against 20 
mM sodium phosphate, pH 6.2, 0.3 mM NaCl, 1 M urea, 1 mM DTT, 1 mM EDTA and 10% 
(w/v) glycerol. The dialyzed sample was then concentrated to approximately 5 ml, of which 500 
µl (5 mg protein) was loaded onto the Mono S column (Figure 4.8). The other 4.5 ml was 
dialyzed against integrase storage buffer, aliquoted, frozen in liquid nitrogen and stored at -80ºC.  
 
The fall-through peak observed was examined by SDS-PAGE (Figure 4.9). No clear band for 
integrase was observed (which had been the case throughout the experiments), but tube 1 was 
nevertheless dialyzed into integrase storage buffer, aliquoted, frozen in liquid nitrogen and stored 
at -80ºC.  
 
Jenkins et al. (1996) also used gel filtration chromatography (Superdex 200 column) to determine 
the multimeric state of the mutated integrase in solution, and determined that the protein migrated 
to a predicted position of a tetramer (relative to globular protein standards), when present at 
concentrations higher than 4 mg/ml, and to a predicted position of a dimer, when present at 
concentrations lower than 0.4 mg/ml. They could however, not determine whether the active 
multimer is dimeric, tetrameric, or higher order. Wanting to only purify the mutated integrase 
protein, and not do structural studies and analyses, this part was not included in the present study. 
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Figure 4.8: Chromatogram representative of elution of HIV-1 integrase from Mono S (MonoSIntegrase01).  
Approximately 500 µl of sample was loaded onto the column (at a protein concentration of 9.5 mg/ml) 
and fractions of 2.5 ml and later 1 ml (see profile) were collected. The blue line represents the 
absorbance at 280nm, while the faint grey line represents the conductivity reading.   
 
 
 
Figure 4.9: Reducing SDS-PAGE (15% acrylamide gel) representative of the peak obtained in MonoSIntegrase01 
(Figure 4.8). Lanes represent peqGOLD Protein Marker II (Lane 1); Tube 1 (Lane 3) and Tube 2 (Lane 
4).  
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4.3.3 
 
Integrase activity assay 
4.3.3.1 
 
Target DNA 
Target DNA for the integrase activity assay was prepared by linearizing pBluescript SK with 
SmaI, and coating wells of multititre plates. These plates were incubated for 2 hours at 37ºC and 
stored overnight in a humidified environment at 4ºC. E. coli DH5α cells were transformed with 
pBluescript SK (at a concentration of 50 ng/µl), and plasmids were isolated using the Wizard® 
Plus Midipreps DNA Purification System. This was required to amplify the plasmid in sufficient 
quantity to coat the microtitre plate to be used in the integrase activity assays.  
 
Isolated plasmids were verified to be pBluescript SK by restriction digestion (Figure 4.10) with 
PvuII (expected fragments were approximately 2600 bp and 450 bp) and BglI (expected 
fragments were approximately 1700 bp and 1200 bp). 
 
The sizes of the upper bands obtained were approximately 2900 bp for lanes 3-6 and 2000 bp for 
lanes 8-11. Sizes for lower bands obtained were approximately 400 bp for lanes 3-6 and 1400 bp 
for lanes 8-11. These sizes were considered close enough to those expected to confirm the 
isolation of the pBluescript SK plasmid. The isolated pBluescript was linearized with SmaI for 
use in the integrase activity assay, by way of a single restriction digest (Figure 4.11).  
 
The expected size of the linearized pBluescript was 3000 bp, which was obtained for the 
linearized plasmids isolated. This result was considered evidence of successful linearization of 
the plasmid. These correctly sized bands were then isolated from the gel using the QIAquick Gel 
Extraction Kit (QIAGEN, Germany). Concentrations of the plasmids were determined, and 1 µg 
per well was used in the integrase activity assay. 
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Figure 4.10: Fragments obtained after restriction digestion of isolated pBluescript SK. Lanes represent Fermentas  
Gene Ruler 1 kb DNA Ladder (Lane 1); Plasmids isolated and digested using PvuII (Lanes 3 – 6) and 
restriction of plasmids using BglI (Lanes 8 – 11). 
 
 
 
Figure 4.11: pBluescript linearized with SmaI restriction endonuclease. All lanes represent restriction digest with  
 SmaI and Lane 1 contains Fermentas Gene Ruler 1 kb DNA Ladder. 
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No activity for either of the stored samples of integrase was detected, neither the stored sample 
from Ni2+-chelation chromatography nor that from the cation exchange column. Negative 
controls included omitted donor DNA, omitted target DNA, omitted integrase and a blank, 
containing only integration buffer. No active integrase was available for running a positive 
control, which prevented proof being obtained for successful assay conditions for HIV-1 
integrase. 
 
4.4 
 
Conclusion 
Having received an HIV-1 integrase gene already cloned into the expression vector, pET15b, it 
was relatively quick and simple to express the integrase in the cells recommended, E. coli 
BL21(DE3). This E. coli strain is accepted as the optimal strain for HIV-1 integrase expression, 
as can be seen in it’s use in various studies involving this protein (Au et al., 2000, Jenkins et al., 
1996, Wang et al., 2004, Sherman and Fyfe, 1990).  
 
However, expression of the protein was inconclusive by inspection of the SDS-PAGE gels. 
Western blots confirmed the presence of HIV-1 integrase, but it is clear that the need to use 
Western blots to detect the protein indicates relatively low expression levels by this strain of E. 
coli.   
 
Purification from the HiTrap Chelating HP column yielded a clear eluted peak during the 
imidazole gradient, although no activity could be detected for the purified protein. Again, 
Western blots were required to prove that integrase was isolated, further confirming low levels of 
expression. The peak tubes were pooled, dialyzed and loaded onto the Mono S column, where the 
acquired flow-through peak (no elution peak was visible, Figure 4.8) was tested for activity, but 
no activity was detected.   
 
Au et al. (2000) also purified integrase using a His-tagged integrase and thus a Ni2+-chelating 
Sepharose column, whereas another study by Wang et al. (2004) purified integrase using Ni-
NTA magnetic agarose beads and microtiter plate technology. In the study by Wang et al. (2004), 
activity of the purified integrase was measured using a radioactive integration assay where 
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products of the integration reaction were analyzed on 20% polyacrylamide denaturing gels, which 
were then subjected to autoradiography or phosphorimaging as described in Wang et al. (2001). 
 
Further studies could include examining the possibility of using other E. coli strains for the 
expression of integrase (as was done with HIV-1 protease). Higher levels of expression would 
make identification of the protein easier, as well as improve the purification and study thereof. 
Due to the very low concentrations of integrase throughout the experiments, activity was not 
likely to be detected, and with improved expression and therefore higher protein concentrations, 
detecting activity would be a more achievable aim. Using an alternative integration activity assay 
such as that used by Wang et al. (2004) may also improve detection of active integrase.   
 
Storing samples between experiments could also be minimized, as activity might have been lost 
when the protein was frozen to be kept for later experiments (as mentioned in section 4.2.2.4.2). 
Although the activity assay was questioned when no positive results were obtained, as well as not 
being able to include a positive control into the experiment, the low concentrations throughout 
the study made the inactivity, or the lack of observable activity, a realistic outcome. Chang et al. 
(1996), however, stated that the integration activity in the assay is very specific and easily 
observable and the readings of the measurements should be 2 – 3-fold those of the various 
negative controls included. This was not observed in our study, which further fuels the 
conclusion that activity was either too low to be detected, or completely absent. 
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Chapter 5 
 
Kinetics of HIV-1 Protease 
5.1 
 
Introduction 
Human immunodeficiency virus contains a protease which is responsible for the processing of 
the gag and gag-pol precursors to yield structural proteins and enzymes of the mature virus. The 
structure of the enzyme and its specificity has been well studied (Tie et al., 2007). This enzyme, 
which is essential for HIV maturation and infectivity, is an important target for AIDS therapy 
(Hornak and Simmerling, 2007). Many potent HIV protease inhibitors have been tested (Ghosh et 
al., 2007). 
 
In vitro, in vivo, and clinical experiments have shown that some of these inhibitors have anti-HIV 
properties (Roche et al., 2008). Therapeutic use of an HIV protease inhibitor is adversely 
impacted by viral drug resistance resulting from mutations of the protease gene and selection of 
resistant strains in the presence of inhibitors (Asjö and Langeland, 2008). Resistance to protease 
inhibitors has also been demonstrated in HIV grown in cultured cells (Krowicka et al., 2008). 
The resistance problem needs to be overcome before this line of therapy can be effective. 
 
How structural mutation of HIV protease renders the inhibitor ineffective is a field of intense 
study. Resistant mutants can apparently retain sufficient enzyme activity but specifically be less 
sensitive to inhibition. Although there are several reports of kinetic data for HIV protease 
mutants, no method has been developed to assess in vivo processing and resistant potential for 
mutant enzymes (Tang and Hartsuck, 1995). 
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In the presence of inhibitors, the overall processing activity in a virion is a balance of protease 
processing efficiency (kcat / Km) and inhibition efficiency (specified by inhibition constant, Ki, 
and inhibitor concentration, [I]).  
 
In the immature virions, the p55 gag polyproteins form a ‘gag shell’ with the p17 ends anchored 
in the outer lipid membrane. The p55 subunits are cylinder shaped and are densely packed in an 
icosahedral two-dimensional array (Nermut et al., 1994). The gag portion of the p190 gag-pol 
precursor co-assembles with p55 in the ‘gag shell’ while the pol cylinder (including protease) is 
located in the space inside the ‘gag shell’ (Figure 5.1). 
 
 
 
Figure 5.1: Schematic presentation of the packing relationships of p55 gag and p190 gag-pol inside of a membrane  
section of immature HIV virion. Immediately inside of the lipid membrane is a layer ‘gag shell’ which 
contains tightly packed, cylinder shaped p55 gag precursor units organized in icosahedral pattern. Each 
p55 unit is anchored in the membrane by an N-terminal myristoyl group. The two longer cylinders 
represent p190 gag-pol with the protease dimer located adjacent to the ‘gag shell’. The processed 
protease dimer (dimensions about 39 Ǻ x 53 Ǻ) is unable to enter the cavity (diameter about 35 Ǻ) in the 
‘gag shell’, so the processing of the gag is assumed to be sequential from the p6 to p17 as marked on the 
p55 cylinder. The packing dimensions of p55 in the ‘gag shell’ are taken from the work of Nermut et al., 
(1994). In each immature virion there are about 1890 molecules of p55 of which 95 are in the p190 form 
[Taken from Tang and Hartsuck, 1995]. 
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To initiate processing, the protease is likely freed by self-excision from the precursor (Co et al., 
1994, Louis et al., 1994), then by protease catalyzed release. The pores in the ‘gag shell’ are too 
small (Nermut et al., 1994) for the protease to penetrate. Thus, the processing must proceed 
through the accessible cleavage sites on the inner surface of the ‘gag shell’. This near sequential 
processing mechanism is supported by the observation that p39 (p17-p24) is the major processing 
intermediate (Gowda et al., 1989a and Gowda et al., 1989b) and is consistent with the final 
locations of individual gag subunits in the mature virion. 
 
The kinetics for the hydrolysis of membrane-fixed gag should follow steady-state kinetics. In an 
analogous case, the hydrolysis of membrane-located phosphatidylcholine by phospholipase A2 
(Kupferberg et al., 1981) conforms with Michaelis-Menten kinetics without processivity by the 
enzyme toward the substrate surface. Therefore, the kinetics of the intra-virion processing should 
be appropriately described by kinetics characteristic of [S] « Km.  
 
The purpose of this study was to produce active protease for inhibitor screening studies from 
herbal remedies. A protein with similar kinetic properties to the wild-type viral protease (in terms 
of substrate affinity, maximal activity and inhibitor constant) was, therefore, pursued. 
 
5.2 
 
Methodology 
5.2.1 
 
Monitoring proteolytic activity of HIV-1 protease 
For kinetic studies, the HIV-1 protease fluorogenic activity assay [using HIV-FRET(1) as 
substrate] was used (section 3.2.3). The proteolytic activity was monitored by varying the 
enzyme concentration, while keeping the substrate concentration constant (at 100 µM). Stored 
partially purified recombinant protease (section 3.3.3.2) was thawed, the concentration 
determined (by using the Bradford protein assay) and used in the fluorogenic assay at different 
concentrations ranging from 0.05 mg/ml to 0.5 mg/ml. A control reaction containing 0.5 mg/ml 
pepstatin A was used to inhibit activity, and all experiments were carried out in triplicate. 
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5.2.2 Determination of Km and k
 
cat 
To determine the Km and kcat of HIV-1 protease HIV-FRET(1) was varied between 0.05 and 1 
mM. The enzyme concentration was kept constant at 0.125 mg/ml. The activity was monitored 
continuously taking fluorescence readings every 5 minutes over an hour period. All experiments 
were performed in triplicate. 
 
5.2.3 
 
Determination of the inhibitor constant of pepstatin A 
Pepstatin A concentrations were varied between 0.005 mg/ml and 0.05 mg/ml and protease 
activity assayed using a substrate range determined in 5.2.2. The Ki of pepstatin A was 
determined accordingly with all experiments carried out in triplicate. 
 
5.3 
 
Results and Discussion 
5.3.1 
 
Monitoring proteolytic activity of HIV-1 protease 
Fluorescence readings (enzyme activity) increased, as enzyme concentration increased, as was to 
be expected (Figure 5.2). Monitoring proteolytic activity of HIV-1 protease yielded curves 
similar to those obtained in Matayoshi et al. (1990).  
 
It was decided to use protease, in the remainder of the kinetic study, at a concentration of 0.125 
mg/ml. This concentration gave the most constant and steadily increasing values (data not 
shown). 
 
5.3.2 Determination of Km and k
 
cat 
Substrate concentration was varied to obtain a concentration range at which remaining kinetic 
and inhibitor studies could successfully be examined. The highest concentration was kept at 1 
mM, at which the substrate was stored prior to use. Initial experiments used a fixed time assay 
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(30 minutes) as described in section 3.2.3. Concentrations were evaluated as low as 5 µM. A 
typical hyperbolic curve was eventually determined to range between substrate concentrations of 
10 µM to 100 µM (Figure 5.3). Since the maximal activity was not reached at 100 µM, it was 
decided to perform further kinetic studies using [S] up to 500 µM, and measuring activity 
continuously.   
 
 
 
Figure 5.2: Graph illustrating increase in fluorescence intensity with increase in HIV-1 protease concentration.   
 
Progress curves for the enzyme-catalyzed reaction were then constructed at each substrate 
concentration where fluorescence was plotted against time (data not shown). These progress 
curves were used to determine the initial velocity (vo) at these different substrate concentrations, 
which was then plotted against the substrate concentrations in a Michaelis-Menten plot.  
 
The vo values obtained from these progress curves were converted to values of µM/min using the 
molar extinction coefficient of EDANS, 5438 M-1cm-1 (Matayoshi et al., 1990). These values 
were used to construct a double-reciprocal (Lineweaver-Burk) plot for determination of the Km 
and Vmax values of HIV-1 protease (Figure 5.4). The Km of HIV-1 protease in this study was 
determined to be 592 µM and Vmax was determined to be 0.59 µM/min.  
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Figure 5.3: Michaelis-Menten curve showing an increase in fluorescence intensity with an increase in substrate 
concentration. Substrate and enzyme were incubated in the dark for 30 minutes prior to stopping the 
reaction with trifluoroacetic acid and measuring fluorescence. 
 
The determined Km value (592 µM) was much higher than the Km obtained for protease referred 
to in Matayoshi et al. (1990), which was 103 ± 8 µM. In previous reports where synthetic peptide 
substrates for HIV-1 PR were studied, Km values in the millimolar range were obtained (Darke et 
al., 1988, Darke et al., 1989, Moore et al., 1989). In Ido et al. (1991), a Km of 2.3 mM was also 
obtained (at a pH of 4.6). Richards et al. (1990) investigated several chromogenic substrates for 
HIV-1 protease and Km values ranged between 6 and 22 µM. Different assays and different 
substrates thus result in different values for Km and should be understood accordingly. The Vmax 
obtained (0.59 µM/min) was also higher than the Vmax in Matayoshi et al. (1990), which was Vmax 
± SD = 164 ± 7 nM/min, although less so than the Km.  
 
The substrates used in the study by Richards et al. (1990) explored other determinants for 
proteinase recognition, and focused on the Leu-Ala cleavage site at one of the CA/NC junctions, 
compared to our study, where the substrate corresponded to the p17/p24 cleavage site and the 
Tyr-Pro peptide bond was involved. Ido et al. (1991) also used a substrate based on the p17/p24 
cleavage site, but used reverse phase HPLC for analysis of the cleavage products.  
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Figure 5.4: Lineweaver-Burk plot used to determine the Km and Vmax values of HIV-1 protease. 
 
The kcat was then determined for HIV-1 protease from the Vmax value on the assumption that a 
relative molecular mass of the active enzyme (dimer) is 22 000. kcat was determined as being     
31 s-1, which was comparable to the kcat referred to in Richards et al. (1990), which was 20 s-1. 
Other kcat values included 2.4 s-1 (at a pH of 4.6) obtained for wild-type protease in Ido et al. 
(1991) and 4.9 s-1 reported in Matayoshi et al. (1990). Once again values obtained for this 
parameter varied a great deal, and seemed to be dependent on various assay conditions.  
 
5.3.3 
 
Determination of the inhibitor constant of pepstatin A 
Inhibitor (pepstatin A) concentrations were varied between 0.005 mg/ml and 0.05 mg/ml, and 
concentrations of 0.01 mg/ml, 0.02 mg/ml and 0.03 mg/ml were eventually used to determine the 
Ki of the inhibitor (Figure 5.5). 
 
The vo was again determined at various substrate concentrations (0.1 mM to 0.9 mM) and 
converted to µM/min. These values were used in a Dixon plot to determine Ki of pepstatin A. 
According to a Dixon plot, the Ki of an inhibitor is the value on the x-axis at which all the linear 
graphs on the figure intersect. The inhibitor constant for pepstatin A was determined to be 0.93 
µM, and according to the Dixon plot exhibited the properties of a competitive inhibitor.    
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This value was much higher than the inhibitor constant referred to in Matayoshi et al. (1990), 
which was 17 nM. Other studies including Richards et al. (1989) and Kräusslich et al. (1989), 
however, reported Ki values of pepstatin A in the micromolar range (0.4-250 µM), and a number 
of factors were reported as possible reasons for the differences in values obtained for this 
inhibitor constant, including differing substrates, assay conditions and preparations of HIV-1 
protease (Matayoshi et al., 1990).      
 
  
 
Figure 5.5: Dixon plot used to determine the Ki of pepstatin A.  
 
5.4 
 
Conclusion 
Although values in literature for kinetic parameters differ from each other, and also from the 
values obtained in this study, if relativity is kept in mind, any of the methods or conditions can be 
employed for possible inhibitor studies. 
 
Protease produced in this study showed activity and comparable kinetic parameters and is 
believed to have folded correctly. Thus, as mentioned in the introduction of this chapter, drug 
screening employing protease produced from methods developed in this study would be feasible. 
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Values obtained for different parameters could then be compared to values obtained in this study, 
to allow for relative analysis. 
 
In conclusion, active partially purified recombinant HIV-1 protease was produced for use in 
future studies testing possible therapeutic drugs against HIV.  
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Chapter 6 
 
Concluding Remarks 
Screening of medicinal plant extracts for inhibitory properties against, for example, HIV/AIDS 
must necessarily be performed in scientifically objective ways. Screening is investigated against 
the HIV components protease, integrase and reverse transcriptase. In the present study, the aims 
were to produce active recombinant HIV-1 protease and integrase, for the purpose of screening 
medicinal plant extracts. 
 
6.1 
 
HIV-1 protease 
Active recombinant HIV-1 protease was produced by cloning and expressing it in the E. coli 
strain ROSETTA(DE3)pLysS. Expression and purification of the protein were based on methods 
described in Ido et al. (1991), although other methods are available as referred to in Chapter 3, 
such as Rittenhouse et al. (1990). Expression was optimal at 37°C for 3 hours, and with an IPTG 
concentration of 0.4 mM (Figure 3.12). Affinity chromatography was used for purification of the 
protease (HiTrap HP columns). This nickel-affinity column was directed against the poly-
histidine tag present in the pET28b(+) vector that was used for expression of the protease. Elution 
of the protein was accomplished between 600 and 800 mM of imidazole. Western blots 
confirmed the presence of the protein using an antibody specific for the poly-histidine tag (Figure 
3.16). Further purification was halted, as too much protein was lost during gel filtration 
chromatography, and kinetic studies were performed on the acquired partially purified HIV-1 
protease.  
 
Kinetic parameters for the protease were determined, using a HIV-1 protease fluorogenic activity 
assay described in Lam et al. (2000), to be Km 592 µM, Vmax 0.59 µM/min and kcat 31 s-1. 
Alternative methods for measuring protease activity are available as referred to in Chapter 3, such 
as reverse phase HPLC separation of cleavage products of a synthetic substrate described by 
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Wang et al. (1996), but the assay used in the present study proved ideal for measuring kinetic 
properties of the enzyme. 
 
Active recombinant HIV-1 protease was thus produced, as outlined in the aims of the project, and 
proved to have similar kinetic properties as the wild-type HIV-1 protease, and hence can be used 
for future studies including screening of medicinal plant extracts.   
 
6.2 
 
HIV-1 integrase 
Recombinant HIV-1 integrase was produced by expressing it in the E. coli strain BL21(DE3). 
Expression and purification of the protein were based on methods described in Jenkins et al. 
(1996), although other methods are available as referred to in Chapter 4 such as Au et al. (2000) 
and Wang et al. (2004). Expression was carried out at 37°C for 3 hours, and with an IPTG 
concentration of 0.4 mM. Western blots were used to confirm the presence of integrase after 
expression, again by means of an antibody specific for the poly-histidine tag (Figure 4.3). Nickel-
affinity chromatography was again used for purification of the integrase due to the histidine tag 
present in the pET15b vector that was used for expression of the integrase. After purification 
from the nickel-affinity column Western blots were used to confirm the presence of the integrase 
in the tubes that reached maximum absorbances at 280 nm (Figure 4.7). Further purification was 
halted due to already low concentration of integrase (expressed at very low concentrations), and 
thus the inability to load enough sample onto the Mono S ion-exchange column used by Jenkins 
et al. (1996). No enzyme activity was measured for the partially purified integrase (using a non-
radioactive enzyme linked assay). HIV-1 integrase was thus expressed in such low concentrations 
throughout, that the process employed needs to be modified to obtain protein in concentrations 
high enough to further measure and utilize it’s activity. 
 
Modifications may include investigation into expression conditions, such as the temperature 
(including possible low temperatures), time of incubation and concentration of IPTG added, as 
was done with HIV-1 protease. The expressing strain could also be modified and different strains 
could be investigated (also as was done for HIV-1 protease). A different assay could also be 
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employed for activity measurements, for example that referred to in Chapter 4 by Wang et al. 
(2004), where a radioactive integration assay is used for increased sensitivity.    
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